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SUMMARY 
The objective of this thesis was to investigate the role of the transcription factor 
nuclear factor erythroid 2-related factor 2 (Nrf2) during inflammatory and 
degenerative processes. Nrf2 can be activated by reactive oxygen species (ROS) 
and induces the expression of genes encoding for cytoprotective and antioxidant 
enzymes. It has already been shown that elevated levels of ROS are present during 
inflammation, indicating a possible involvement of Nrf2. 
The study demonstrated that Nrf2 is not only cytoprotective and antioxidative 
during inflammation, but has also regulatory functions in these processes. 
Experiments using macrophages showed that early pro-inflammatory mediators 
initiate a double tracked molecular machinery. Besides from the well-known fast-
acting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
signaling, which initiates the acute phase of inflammation, these mediators also 
induce Nrf2 with a time delay. The activation of Nrf2 depended on 
NADPH oxidase 2 mediated ROS production and extracellular signal-regulated 
kinase (ERK) as well as p38 mitogen-activated protein kinase (p38 MAPK) activity. 
This resulted in an up-regulation of cytoprotective enzymes, especially the 
anti-inflammatory enzyme heme oxygenase-1 (HO-1), which in turn is able to 
inhibit NF-κB. 
In an in vitro model of Rheumatoid Arthritis, it was shown that sulforaphane (SFN) 
has opposing effects on naïve and inflammatory synoviocytes. SFN treatment 
induced cytoprotection due to Nrf2 activation in TNF-α untreated naïve 
synoviocytes, but apoptosis in TNF-α pre-treated inflamed synoviocytes. This 
induction of apoptosis resulted at least in part from an Nrf2-driven inhibition of 
the pro-inflammatory transcription factors activator protein-1 (AP-1) and NF-κB. 
Nrf2 deficient mice (Nrf2-KO) were used to investigate the role of Nrf2 in the 
mouse model of sclerosing cholangitis induced by a 3,5-diethoxycarbonyl-1,4-
dihydrocolidine (DDC) diet. Nrf2-KO mice exhibited more severe liver damage 
indicated by enhanced bilirubinostasis, increased proliferation of cholangiocytes 
and increased infiltration of leukocytes compared to the DDC-treated wild type 
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mice. Moreover, the induction of HO-1 was significantly reduced in Nrf2-KO mice 
and the secretion of several pro-inflammatory cytokines was increased compared 
to DDC-fed wild type mice. 
Transgenic amyloid precursor/presenilin1 (APP/Psen1) mice, a well-established 
mouse model of Alzheimer’s disease (AD), were used to investigate a possible role 
of Nrf2 during the progression of AD. The study showed that the kavalactone 
methysticin activated Nrf2 in the hippocampus and cortex. Therefore, APP/Psen1 
mice were treated weekly with methysticin by oral gavage over a period of 
6 months. Behavioral tests demonstrated that methysticin application significantly 
attenuated the long-term memory decline of the APP/Psen1 mice. 
Immunohistochemical stainings revealed that this protective effect correlates with 
a significant reduction of inflammation in the brain. 
In summary, various in vitro and in vivo models of inflammatory and degenerative 
diseases were used in this thesis to characterize the role of Nrf2 in inflammation. 
The resulting data indicate an anti-inflammatory role for Nrf2. In conclusion, Nrf2 
may be a crucial factor involved in the resolution of inflammation. 
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ZUSAMMENFASSUNG 
In dieser Arbeit wurde die Rolle des Transkriptionsfaktors Nuclear factor 
erythroid 2-related factor 2 (Nrf2) in der Inflammation und Degeneration 
untersucht. Nrf2 kann durch reaktive Sauerstoffspezies (engl. reactive oxygen 
species ROS) aktiviert werden und induziert die Expression von Genen, die für 
zytoprotektive und antioxidative Enzyme codieren. Es ist bereits gezeigt, dass 
während des Entzündungsprozesses ein erhöhtes Maß an ROS entsteht, daher ist 
eine Rolle von Nrf2 in der Inflammation anzunehmen. 
Es konnte gezeigt werden, dass Nrf2 während der Inflammation nicht nur eine 
zytoprotektive und antioxidative Funktion übernimmt, sondern ebenfalls regulativ 
in die Inflammation eingreift. Die Experimente mit Makrophagen haben gezeigt, 
dass früh pro-inflammatorische Mediatoren eine zweigleisige molekulare 
Maschinerie in Gang setzen. Abgesehen von dem bekannten schnell agierenden 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) Signalweg, 
der die Akutphase der Inflammation initiiert, induzieren diese Mediatoren 
zeitversetzt dazu Nrf2. Die Aktivierung von Nrf2 hing dabei von der NADPH 
oxidase 2 vermittelten Produktion von ROS und der Aktivität der extracellular 
Signal-regulated kinase (ERK) sowie der p38 mitogen-activated protein kinase 
(p38 MAPK) ab. Diese Aktivierung führte zur Hochregulation von zytoprotektiven 
Proteinen, insbesondere des anti-inflammatorischen Enzyms Hämoxigenase-1 
(HO-1), die wiederum in der Lage ist NF-κB zu inhibieren. 
In einem in vitro Modell der Rheumatoiden Arthritis konnte gezeigt werden, dass 
Sulforafan (SFN) entgegengesetzte Effekte auf naïve und entzündliche 
Synovialozyten hat. In TNF-α unbehandelten Synovialozyten induzierte SFN eine 
Zytoprotektion aufgrund von Nrf2 Aktivierung, jedoch Apoptose in TNF-α 
vorbehandelten Synovialozyten. Diese Induktion der Apoptose basierte zumindest 
zum Teil auf der Nrf2 gesteuerten Inhibition der pro-inflammatorischen 
Transkriptionsfaktoren activator protein-1 (AP-1) und NF-κB. 
An der Nrf2-defizienten Maus (Nrf2-KO) sollte die Rolle von Nrf2 im Mausmodell 
der Sklerosierenden Cholangitis untersucht werden, die durch eine Fütterung von 
ZUSAMMENFASSUNG 
4 
3,5-diethoxycarbonyl-1,4-dihydrocolidine (DDC)-haltigem Futter erzeugt wurde. 
Nrf2-KO zeigten eine erhöhte Leberschädigung mit erhöhter Bilirubinostase, 
stärkeren Cholangiozytenwucherungen und einer erhöhten Infiltration von 
Leukozyten im Vergleich zur DDC-gefütterten Wildtyp-Maus. Im Vergleich zu den 
DDC-gefütterten Wildtyp-Mäusen, war die Induktion von HO-1 bei der Nrf2-KO 
Maus signifikant reduziert und die Ausschüttung einiger pro-inflammatorische 
Zytokine erhöht. 
Zur Untersuchung der Rolle von Nrf2 in der Alzheimer Demenz (AD) wurden 
transgene amyloid precursor protein/presenilin1 (APP/Psen1) Mäuse als Modell 
genutzt. Diese Studie hat gezeigt, dass die Behandlung mit dem Kavalacton 
Methysticin Nrf2 im Hippocampus und Cortex aktiviert. Aus diesem Grund wurden 
APP/Psen1 einmal wöchentlich über einen Zeitraum von 6 Monaten mit 
Methysticin per Schlundsonde behandelt. Verhaltensbiologische Untersuchungen 
zeigten, dass die Methysticinbehandlung die kognitive Verschlechterung der 
APP/Psen1-Maus signifikant verminderte. Immunhistologische Experimente 
belegten, dass dieser protektive Effekt mit einer signifikanten Verringerung der 
Entzündungsreaktion korreliert. 
Zusammenfassend kann gesagt werden, dass unter Nutzung verschiedener in vitro 
und in vivo Modelle für inflammatorische und degenerative Erkrankungen in 
dieser Arbeit gezeigt werden konnte, dass Nrf2 anti-inflammatorisch wirkt. Aus 
diesem Grund könnte Nrf2 ein wichtiger Faktor sein, der bei der Aufhebung 
entzündlicher Vorgänge maßgeblich involviert ist. 
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ABBREVIATIONS 
ab antibody 
Aβ amyloid-beta 
ACSF artificial cerebrospinal fluid 
AD Alzheimer’s disease 
AEC 3-amino-9-ethylcarbazole 
AIA antibody induced arthritis 
APP amyloid precursor protein 
approx. approximately 
APS ammoniumpersulfate 
aqua dest. distilled water (lat.: aqua bidestillata) 
ARE antioxidative response element 
AUC area under the curve 
BCA biocinchoninic acid 
BMDM bone-marrow derived macrophages 
bp base pairs 
BSA bovine serum albumin 
BW body weight 
cAMP cyclic adenosine monophosphate 
CCL2 chemokine (C-C motif) ligand 2 
CCL4 chemokine (C-C motif) ligand 4 
cDNA complementary DNA 
Ck19 cytokeratin19 
CND-bZIP Cap’n’collar/basic leucine zipper 
CO carbon monoxide 
Coll1a collagen type 1a 
CR1 complement receptor 1 
CREB cAMP Response Element Binding Protein 
CXCL1 chemokine (C-X-C motif) ligand 1 
DCF 2',7'-dichlorofluorescein 
DDC diethyl 1,4-dihydro-2,4,6-trimethyl-3,5-pyridinedicarboxylate 
DLR dual luciferase reporter gene 
DMEM Dulbecco’s Modified MEM 
DMSO dimethyl-sulfoxide 
DNA deoxyribonucleic acid 
dNTP 2’-deoxynucleotide-5’-triphosphate 
DPI diphenylene iodonium 
dsDNA double stranded DNA 
DTT 1,4-dithiothreitol 
E. coli Escherichia coli 
EDTA ethylendiamin-tetraacetate 
ELISA enzyme-linked immunosorbent assay 
EpRE electrophile response element 
ERK Extracellular signal-regulated kinase 
EtOH ethanol 
FCS fetal calf serum 
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GFP green fluorescent protein 
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HO-1 heme oxygenase 1 
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IFN interferon 
IgG immunoglobulin G 
IHC immunohistochemistry 
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  inhibitor 
IKK IκB kinase 
IL-1β interleukin-1β 
IL-1RA interleukin-1 receptor antagonist 
IL-5 interleukin-5 
IL-6 interleukin-6 
IL-8 interleukin-8 
IL-10 interleukin-10 
IL-12 interleukin-12 
JNK c-Jun N-terminal kinases 
kb kilobase pair (1000 bp) 
KCl potassium chloride 
Keap1 kelch-like ECH-associated protein 1 
KO knockout 
LB Luria-Bertani-medium 
LCM L929 culture medium 
LPS lipopolysaccharides 
Luc luciferase 
M-CSF macrophage colony-stimulating factor 
MAPK mitogen-activated protein kinase 
MCS multiple cloning site 
MEK1/2 Mitogen-activated protein kinase kinase 
MEM Eagle’s minimal essential medium 
MgCl2 magnesium chloride 
MIQE Minimum Information for Publication of Quantitative Real-Time 
 PCR Experiments 
MOPS 3-(N-morpholino)propanesulfonic acid 
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NAC N-acetyl-cysteine 
NaCl sodium chloride 
Neh Nrf2-ECH homology 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells 
NOX NADPH oxidase 
NP40 commercially available detergent (Tergitol-type NP40) 
NQO1 NAD(P)H quinone oxidoreductase 1 
Nrf2 nuclear-factor erythroid2 related factor 2 
NSAID nonsteroidal anti-inflammatory drug 
OD optical density 
OriC origin of replication 
PAA polyacrylamide 
PAGE polyacrylamide-gel electrophoresis 
PAMP pathogen-associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PeSt penicillin/streptomycin 
PFA paraformaldehyde 
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PI3K Phosphoinositide 3-kinase 
PLB passive lysis buffer 
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PSC primary sclerosing cholangitis 
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QC quality control 
qRT-PCR quantitative reverse transcriptase-polymerase chain reaction 
RA Rheumatoid Arthritis 
RE response element 
rev reverse 
RIPA buffer Radioimmunoprecipitation assay buffer 
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RNA ribonucleic acid 
RNase ribonuclease 
ROS reactive oxygen species 
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RPMI 1640 Roswell Park Memorial Institute medium 1640 
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RT reverse transcriptase 
SA spontaneous alteration 
SD standard deviation 
SDHA succinate dehydrogenase, subunit A 
SDS sodium dodecyl sulfate 
sec seconds 
SEM standard error of the mean 
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SFN sulforaphane 
shRNA small hairpin RNA 
sMaf small Maf 
SOC super optimal broth with catabolite repression 
SOP standard operating procedure 
SSC secondary sclerosing cholangitis 
ssDNA single stranded DNA 
TAE Tris-Acetate-EDTA-buffer 
TBP TATA-binding protein 
TBS tris-buffered saline 
TBS-T tween supplemented TBS 
TCF ternary complex factor 
TLR2 toll-like receptor 2 
TLR4 toll-like receptor 4 
Tm melting temperature 
TNF-α tumor necrosis factor α 
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TRX thioredoxin 
TWEAK tumor necrosis factor (ligand) superfamily, member 12 
TXNRD1 thioredoxin reductase 1 
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VEGF vascular endothelial growth factor 
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w/v weight/volume 
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YWHAH Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
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INTRODUCTION 
Nrf2 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor, which 
belongs to the family of Cap’n’collar/basic leucine zipper (CND-bZIP) proteins 1. 
Nrf2 exhibits six highly conserved domains commonly known as Nrf2-ECH (Neh) 
domains (see Fig. 1A). Till now the function of these domains is just partly 
described. It is known that Neh1 is the CNC-bZIP domain 1, which allows Nrf2 to 
heterodimerize with other transcription factors like small Maf (sMaf) proteins. The 
Neh2 domain deals as binding domain to Nrf2’s cytosolic repressor called Kelch 
like-ECH-associated protein 1 (Keap1) 2,3. The function of Neh3 is not clearly 
known, but it is believed that this domain plays a role in Nrf2 stability and may 
additionally act as transactivation domain 4. Neh4 and Neh5 deal as the main 
transactivation domains of Nrf2. These domains allow the binding of the cAMP 
Response Element Binding Protein (CREB), which activates intrinsic histone 
acyltransferases 5. For the Neh6 domain it is thought to be involved in the 
degradation of Nrf2 due to the existence of a degron 3. 
 
Fig. 1 Structure of Nrf2 and ARE consensus sequence. The Nrf2 protein consists of 6 functional domains, termed 
Nrf2-ECH domains (Neh). Neh1 is the DNA binding domain. Neh2 represents the binding domain for Nrf2’s 
inhibitor Keap1. Neh4 and Neh5 form the transactivation domain of the protein. Neh3 and Neh6 contain degrons and 
are therefore believed to be involved in the degradation process of Nrf2 (A). Consensus sequence of the conserved 
ARE sequence (B). 
Functionally Nrf2 can be considered as the main regulator in the oxidative stress 
defense and antioxidant response. Nrf2’s transcriptional activity is mediated by a 
highly conserved DNA sequence which is found in the promoter region of Nrf2’s 
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target genes. This sequence is called antioxidant response element (ARE) and its 
consensus sequence is found in Fig. 1B 6. 
General mechanisms 
Under physiological conditions Nrf2 is bound to its naturally occurring inhibitor 
called Keap1 7-9. On the one hand Keap1 deals as an adaptor protein for a Culin3 
associated E3 ligase, which facilitates the polyubiquitination of Nrf2. Thereby Nrf2 
is marked and immediately directed to proteasomal degradation by the 26S 
proteasome. Consequently Nrf2’s half-life is limited to approximately 20 minutes 
(Fig. 2A) 10. On the other hand Keap1 represents the redox-sensitive molecular 
sensor, which regulates Nrf2’s activity 11. This regulation is based on two critical 
thiol groups located at Keap1, which build disulfide bonds after being exposed to 
an oxidant or an electrophile. This leads to a conformational change of the Keap1 
dimer, whereby Keap1 is not further able to bind Nrf2 12,13. As a result, Nrf2 
translocates into the nucleus and heterodimerizes with transcriptional co-
activators like small Maf proteins. There, the heterodimer binds to specific ARE 
sequences within the promoter region of Nrf2’s target genes and up-regulates their 
transcription 6. These target genes include heme oxygenase-1 (HO-1), 
NADP(H) quinone oxidoreductase 1 (NQO1), synthetases, transferases, reductases 
and peroxidases involved in the glutathione and thioredoxin cycle and many 
others which belong to antioxidant and detoxifying proteins (Fig. 2B) 14. Especially 
HO-1 plays a major role during inflammation, because of its anti-inflammatory 
side-product carbon monoxide. 
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Fig. 2 Nrf2/ARE signaling cascade. Under physiological conditions Nrf2 is scavenged by its inhibitor Keap1. 
Keap1 deals as adaptor protein for a cullin-associated E3-ligase, which polyubiquitinates Nrf2 and therefore marks 
the protein for proteasomal degradation (A). In the presence of Nrf2 activators like reactive oxygen species (ROS), 
electrophiles and also receptor-mediated factors, Nrf2 is released from Keap1 due to conformational changes of 
Keap1 or phosphorylation of Nrf2. Afterwards Nrf2 translocates into the nucleus, dimerizes with other transcription 
factors to up-regulate the transcription of its target genes by binding to the cis-acting ARE sequence within the 
promoter (B). 
Alternative mechanisms 
Since much research has already been conducted to investigate Nrf2’s involvement 
in several diseases, recent publications emphasize mechanisms, which differ from 
the before mentioned classical activation scheme. These studies give evidence that 
there are alternative ways, by which Nrf2 can be activated absolutely independent 
from the occurrence of oxidative stress 15. There are studies describing Nrf2 
activation due to phosphorylation by various kinases 16,17,18. Moreover, Kweider et 
al. were able to show that Nrf2 activity is induced independently of ROS in 
trophoblasts due to the treatment with VEGF 19. They demonstrated that the 
underlying signaling cascade was mainly driven by VEGF receptor mediated p38 
MAPK activity. Furthermore, it was shown that in turn Nrf2 was able to induce 
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VEGF expression in return via HO-1 mediated carbon monoxide production 19. 
These and other studies indicate further potential roles of Nrf2 beside the classical 
appearance as a key regulator in redox defense mechanisms. 
Inflammation 
Immunity designates the insensibility of the organism against exterior offenses 
and the ability to counteract these without pathological changes. For that purpose 
the mammalian organism occupies the immune system, which is functionally 
divided into the innate immune system and the adaptive immune system. This 
thesis will focus on the innate immune system being responsible for the initial 
immune response, which takes place within the first hours of inflammation. 
The inflammation (lat.: inflammare) is a complex biological reaction in response to 
harmful stimuli like pathogens, damaged cells or other non-physiological 
substances 20. Basically, the inflammatory reaction is a protective attempt, which is 
designed to remove these injurious substances and to clear the way for tissue 
healing. In the course of inflammation the actual pathogen defense is boosted by 
increasing the accessibility for effector molecules and cells to the center of 
infection, the expansion of infection will be restricted by creating a physical barrier 
and the healing process of affected tissue will be facilitated. The inflammatory 
response in general is characterized by pain (lat.: dolor), redness (lat.: rubor), heat 
(lat.: calor), swelling (lat.: tumor) and loss of function (lat.: function laesa) at the 
region of infection. This is attributed to three pivotal changes of the vascular 
system in the affected tissue. First, an enlargement of the blood vessels diameter 
takes place (vasodilatation) leading to enhancement of the local blood flow and 
simultaneously to a reduction of flow velocity. Second, the endothelial cells get 
activated and express adhesion molecules, which promote the attachment of 
circulating leukocytes to the vascular wall enabling these cells to transmigrate into 
the tissue, also called extravasation 21. Third, increased permeability of the blood 
vessels improve the access of plasma and immune cells to the inflamed region. 
All these changes are found during the acute phase of inflammation and are 
orchestrated by a complex network of activated immune cells, secreted 
inflammatory mediators and downstream signaling processes. Usually these 
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complex mechanisms lead to the removal of the harmful substance with 
subsequent actively induced resolution of inflammation 22. If inflammation further 
perpetuates and amplifies itself, a stage called chronic inflammation develops, 
mostly leading to fatal tissue destruction.  
Cells which are already present in the tissue like resident macrophages and 
dendritic cells are able to distinguish pathogens from host due to the presentation 
of certain receptors on their surface named pattern recognition receptors (PRRs). 
These receptors recognize molecules, which are broadly shared by pathogens, 
collectively referred to as pathogen-associated molecular patterns (PAMPs). Once 
PAMPs are recognized, the macrophages are activated and release inflammatory 
mediators to initiate the acute inflammatory process. These mediators 
subsequently can be recognized by other macrophages and immune cells leading 
to the activation of diverse transcription factors and thus various signaling 
cascades. The main transcription factor involved in this signaling cascade is the 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). NF-κB is 
present as a dimer. In mammals there are five homologous structures known 
which are able to assemble these dimers. Under basal conditions NF-κB is bound to 
its inhibitor IκB and thus inactivated. Under inflammation IκB is phosphorylated 
by IκB kinase (IKK) and NF-κB is released. Activation occurs due to receptor-
mediated signaling, like PRRs and receptors recognizing pro-inflammatory 
cytokines. Active NF-κB translocates to the nucleus and initiates among others the 
transcription of pro-inflammatory mediators like cytokines and chemokines 
leading to the arrangement of further immune responses. 
In the course of inflammation macrophages can develop different phenotypes. On 
the one hand they are basically responsible for the removal of pathogens by 
phagocytosis. These macrophages are characterized by the expression of mainly 
pro-inflammatory markers, boosting the inflammatory response, and are 
designated as M1 (“classically activated) macrophages. On the other hand, these 
cells are also able to exhibit an anti-inflammatory phenotype, called M2 
(“alternatively activated”). In contrast to M1 macrophages, M2 macrophages 
mainly express anti-inflammatory markers and are involved in the resolution of 
inflammation and the subsequent healing process. There are several lines of 
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evidence that macrophage polarization is plastic and that the polarization 
dynamically adapts to changes in the microenvironment 23. This indicates that 
these cells are able to switch between M1 and M2 phenotype in the course of the 
inflammatory response to adapt their functionality to current conditions. It is 
known that this switch is a necessary step for an efficient resolution of 
inflammation and tissue healing. 
Inflammatory mediators and their receptors 
Since such a specialized and well-orchestrated process as the inflammatory 
response needs regulation, the body holds a complex network of inflammatory 
mediators, which are secreted during inflammation. These mediators are called 
cytokines (greek: cyto, cell; kinos, movement) and can be classified by structural 
and functional differences. These mediators distinctly affect the behavior of 
surrounding cells and even the releasing cell itself by effecting the interaction and 
communication between them. The cytokine family includes chemokines, 
interferons, interleukins and cell signaling molecules such as tumor necrosis factor 
(TNF). They are secreted by a broad range of cells, especially immune cells. 
Cytokines can be divided due to their function into pro-inflammatory and 
anti-inflammatory mediators. In this regard pro-inflammatory mediators trigger 
the acute phase of inflammation by activating and attracting further immune cells. 
Anti-inflammatory mediators instead, are released after the acute inflammatory 
process has ended to initiate the regeneration process and tissue healing. 
Generally, there exist matching cell-surface receptors for each cytokine which can 
be classified based on their three-dimensional structure into type I cytokine 
receptors, type II cytokine receptors, immunoglobulin (Ig) superfamily receptors, 
tumor necrosis factor receptor family, chemokine receptors and TGF beta 
receptors. 
Cytokine binding to these receptors activates intracellular signaling cascades 
leading to the modification of cell functions. Such modifications include the 
activation of specific transcription factors like the pro-inflammatory acting NF-κB, 
regulating the transcription of genes encoding for cytokines, chemokines and other 
inflammation-promoting proteins.  
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Cytokines released by “classically” activated macrophages (M1) are basically 
pro-inflammatory, like interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-12 
(IL-12), tumor necrosis factor-α (TNF-α), interferons (IFN) and the chemokine 
interleukin-8 (IL-8). IL-1 and TNF-α play an important role in the activation of the 
endothelium and activation of further macrophages and other surrounding 
immune cells. IL-6 and IFN are able to facilitate macrophage activation. IL-8 
secretion results in the attraction of further immune cells to the center of 
inflammation. In contrast, “alternatively” activated macrophages (M2) express and 
secrete a battery of anti-inflammatory cytokines including interleukin-10 (IL-10) 
and interleukin-1 receptor antagonist (IL-1RA).  
Besides the secretion of cytokines, macrophages also express cytokine-receptors at 
their surface, enabling these cells to perceive inflammatory mediators and adapt to 
current conditions. This empowers the macrophage to switch from the 
pro-inflammatory M1 to the anti-inflammatory M2 phenotype after the recognition 
of appropriate signals. 
Rheumatoid Arthritis 
Rheumatoid Arthritis (RA) is a systemic inflammatory autoimmune disease, which 
manifests oneself in the joints of the exterior limbs. This results in severe 
destruction of the affected joints. Considering the epidemiology of RA, there are 
some important parameters to be mentioned. The prevalence of RA is one per cent 
among world population and increases age-dependently up to two per cent. This 
makes RA the most common inflammatory joint disease worldwide. There are 35 –
 65 new cases per 100000 citizens every year with a three-fold higher risk for 
women to become diseased. 
Up to now, the etiology of RA is most widely unknown and despite intensive 
research in this field there are still several hypothesis regarding the cause and 
development of RA. 
The pathogenesis is characterized by a couple of distinctive symptoms. First and 
foremost, it comes to a synovitis, a massively proliferative and destructive 
inflammation of the membrana synovialis. The membrana synovialis is the inner 
membrane of the joint capsule, which is responsible for the production of the 
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synovial fluid (synovial). Synovitis leads to an extensive thickening of the synovial 
membrane, termed hyperplasia. The primordially 1-2 cell layer thick membrane 
strongly proliferates and gets multi-layered due to hyperplasia. This multi-layered 
cell layer can evolve into an aggressive pannus, which is known to migrate from 
the joints’ attachment points towards the flanking bone and joint cavity. The 
formation and migration of the pannus consequently leads to the destruction of the 
cartilage and bone tissue, finally resulting in the characteristic stiffness of the joint 
namely ankylosis. Due to the fact that the synovial membrane is well vascularized, 
the inflammatory process promotes the infiltration of immune cells into the joint 
cavity. These cells further enhance the inflammatory response by the NF-κB and 
AP-1 mediated secretion of pro-inflammatory cytokines, especially TNF-α and 
IL-1β, thereby assembling a positive feedback loop perpetuating inflammation 24. 
In 2011 Wruck et al. investigated the effects of Nrf2 deficiency in a mouse model of 
RA and clearly demonstrated, that the genetic ablation of Nrf2 results in a more 
severe pathogenesis and joint destruction compared to equally treated wild type 
animals 25. Furthermore, it has been supposed that Nrf2, beside its function in the 
oxidative stress defense, directly interferes with the inflammatory signaling 
pathways 26. These findings give evidence that the Nrf2/ARE signaling pathway 
also undertakes important regulatory functions during RA progression by 
abbreviating the pro-inflammatory process and ameliorating tissue healing and 
regeneration.  
Sclerosing cholangitis 
Sclerosing cholangitis is a common disease of the bile ducts in the liver. Causally 
the sclerosing cholangitis can be differentiated into primary sclerosing cholangitis 
(PSC) and secondary sclerosing cholangitis (SSC). While the cause of PSC is most 
widely unknown 27, the SSC is a result of known pathological processes like a 
precedent insult or disturbance of liver homeostasis. It is believed that the PSC has 
likely an autoimmune basis to its pathogenesis. Secondary causes of sclerosing 
cholangitis include intraductual stone disease, surgical or blunt abdominal trauma, 
intra-arterial chemotherapy as well as existing inflammatory dysregulations like 
pancreatitis 28. The group around ter Borg et al. already demonstrated that 
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repetitive and severe bacterial cholangitis can also lead to the development of SSC 
29. The clinical features of both types of sclerosing cholangitis are similar. Both 
come along with immense proliferation of cholangiocytes resulting in destruction 
of the liver architecture, portal hypertension, inflammation, bilirubinostasis, and 
hepatomegaly in the first and liver cirrhosis in the end stage. Like every 
inflammation-associated disease the pathogenesis of SSC is also accompanied by 
increased oxidative stress. It has already been shown that Nrf2 acts protectively in 
other types of liver disease, as toxin-induced liver injury and fibrosis 30, non-
alcoholic fatty liver and steatohepatitis 31. 
An interesting in vitro approach investigating the gene regulation of hepatocytes 
revealed functional ARE sequences within the IL-6 promoter. This work 
demonstrated that Nrf2 directly up-regulates IL-6 in hepatocytes as well as the 
liver and protects the tissue against 3,5-diethoxycarbonyl-1,4-dihydrocolidine 
(DDC) mediated injury 32. The administration of sulforaphane in a model of 
intestinal ischemia reperfusion mediated liver injury also revealed a protection 
against induced injury due to Nrf2 activation 33. These studies demonstrate the 
importance and necessity of further investigations regarding Nrf2’s role in liver 
diseases. 
Alzheimer’s disease 
Alzheimer’s disease (AD) belongs to the class of neurodegenerative diseases 
designated as dementia, whereby approximately 50 % of dementia is related to AD 
34. AD comprises a progressive degeneration of brain tissue resulting in massively 
impaired cognitive abilities. The onset of AD is predominantly at later age, from 60 
years onward with more women suffering from AD than man 35. This can primarily 
be explained by the fact that women have an increased life expectation compared 
to men 36,37. The incidence of AD increases with age, while up to 5 % of people aged 
65 are affected, 10 to 20 % of people aged 80 or older develop this disease 9,38-40. 
Although much research was initiated in the last decades to investigate the 
changes in the brain responsible for the development of AD, the precise cause and 
progression remains still unknown. AD can be classified into a familial early-onset 
and a sporadic late-onset type. Mutations in three genes are known to be 
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responsible for the familial early-onset type – the amyloid precursor protein 
(APP), presenilin1 (Psen1) and presenilin 2 (Psen2) 8. The most common clinical 
symptom is a gradually worsening ability to remember newly acquired 
information. At that stage neurodegeneration already took place. Beside the loss of 
memory, reduced learning abilities, temporal and spatial disorientation, loss of 
judgment and speech disorders are associated with AD-mediated 
neurodegeneration 41-43. The main histopathological sign of AD is a massively 
shrinking of the neocortex and the hippocampus, both associated with memory 
formation, memory processing and further cognitive abilities. This loss of brain 
tissue is linked to the ongoing death of neurons, whose cause is still under 
investigation. There are two hallmark lesions described which are highly 
associated with neurotoxicity in the progression of AD. Extracellular plaques 
mainly composed of miss-folded amyloid-beta (Aβ) and the formation of 
intracellular neurofibrillary tangles formed by accumulation of 
hyper-phosphorylated tau protein are found in certain brain areas predominantly 
in the hippocampus and cortex 44. The amyloid plaque is composed of two different 
Aβ variants, which differ in length (Aβ1-40 and Aβ1-42). These two peptides are 
formed proteolytically from a large precursor molecule called amyloid precursor 
protein (APP). This amyloidogenic cleavage of APP is conducted sequentially by 
two proteases, the β-secretase and the γ-secretase 45. The resulting Aβ monomers 
are able to oligomerize and even form amyloid plaques. There is evidence that Aβ42 
oligomerizes more easily than Aβ40 and is therefore mainly involved in 
neurotoxicity 14. It is known that the formation of Aβ oligomers as well as 
aggregated amyloid plaque lead to oxidative stress and consequent tissue decay 11. 
Beside these histopathologically observable hallmarks, there exists evidence that 
activation of inflammatory processes and the innate immune response are 
critically involved in the degenerative process of AD (Fig. 3) 46,47.  
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Fig. 3 The amyloid cascade. The amyloid precursor protein is processed by β- and γ-secretase to form Aβ42 
monomers. The monomers tend to form Aβ oligomers, which induce synaptic dysfunction and neurotoxicity. 
Aggregation of Aβ monomers further leads to the formation of Aβ plaques, which induce tau pathology and 
inflammation resulting in severe neuronal loss 7. Modified from Citron M. 2010 (Nature Reviews Drug Discovery). 
In 2009 a genome-wide association study found a genetic link between 
inflammation and AD. In this study the complement receptor 1 (CR1), which is 
involved in the innate immune response, was identified as a risk factor for AD 48. 
Moreover it is known that activated microglia, increased occurrence of 
inflammatory mediators like cytokines and chemokines are found in the amyloid 
plaque affected areas. There are studies, indicating that an anti-inflammatory 
therapy may be beneficial. That was supported by the investigations of McGeer et 
al. in 2007. This human study showed that the incidence for AD is lower in patients 
suffering from arthritis, most of whom used nonsteroidal anti-inflammatory drugs 
(NSAIDs) as therapeutic treatment 46. 
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Aim of the study 
The aim of this thesis was to investigate the general involvement of Nrf2 in the 
inflammatory process and its role during the progression of different kinds of 
inflammation- and degeneration-associated diseases. For this purpose various 
in vitro and in vivo models were conducted to clarify Nrf2’s precise role during 
inflammation in different cell types and tissues. Experiments with THP-1 cells, 
RAW264.7 cells and bone-marrow derived macrophages (BMDM) were realized to 
get a closer look on Nrf2 activation due to the confrontation of these cells with 
several pro-inflammatory mediators. HSE and K4IM cells were used to investigate 
the influence of Nrf2 activity in an in vitro model of RA. In vivo approaches were 
conducted to verify the results from cell culture in animal models for 
inflammation-and degeneration-associated diseases like sclerosing cholangitis and 
Alzheimer’s disease. 
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MATERIALS & METHODS 
Chemicals 
All chemicals were of highest quality and purchased from Sigma Aldrich (Munich, 
Germany), Merck Eurolab/VWR (Darmstadt, Germany) or Carl Roth (Karlsruhe, 
Germany), if not otherwise stated. 
Devices 
1. Horizontal gel chamber (DNA and RNA agarose gels): 
  Sub Cell® GT, Bio-Rad (Hercules; CA USA) 
2. Vertical gel chamber (SDS PAGE): 
  Mini PROTEAN® Tetra Cell, BioRad (Hercules; CA USA) 
3. Western-Blot transfer unit: 
  Trans-Blot® Turbo™ Transfer System, BioRad (Hercules; CA USA) 
4. Power-Supplies: 
  PowerPac™ 300, BioRad (Hercules; CA USA) 
  PowerPac™ HC, BioRad (Hercules; CA USA) 
5. PCR devices: 
  StepOne Plus, Applied Biosystems (Darmstadt, Germany) 
  Veriti™ 96-well Thermal Cycler, Applied Biosystems (Darmstadt, Germany) 
  2720 Thermal Cycler, Applied Biosystems (Darmstadt, Germany) 
  GeneAmp PCR System 2400, Perklin Elmer (Massachusetts 02451, USA) 
6. UV/VIS spectrophotometer 
  NanoDrop™ 1000, Thermo Scientific (Waltham; MA USA) 
7. Microscopes: 
  Eclipse TS 100, Nikon (Düsseldorf, Germany) 
  Eclipse 55i, Nikon (Düsseldorf, Germany) 
  DM IL, Leica (Heidelberg, Germany) 
  BZ-9000, Keyence (Osaka, Japan) 
8. Paraffin embedding device: 
  Histoembedder EG1160, Leica (Heidelberg, Germany) 
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9. Sledge microtome: 
  Slide 4003 E, pfm (Cologne, Germany) 
  SM2000 R, Leica (Heidelberg, Germany) 
10. Centrifuges: 
  Labofuge 200, Heraeus Sepatech (Osterode, Germany) 
  Centrifuge 5417R, Eppendorf (Hamburg, Germany) 
  Universal 32R, Hettich Zentrifugen (Tuttlingen, Germany) 
  Z233M, Hermle Labortechnik (Wehingen, Germany) 
11. Shaking incubator: 
  innova™ 4300, New Brunswick Scientific (Nürtingen, Germany) 
12. Homogenisator: 
  precellys 24, Bertin Technologies (Montigny le Bretonneux, France) 
13. Luminometer: 
  GloMax™ 96 Microplate Luminometer, Promega (Madison, WI USA) 
14. 96-well-plate reader: 
  Infinite® M200, Tecan Deutschland (Crailsheim, Germany) 
15. S1 sterile cell culture bench 
  LaminAir MS 2010 Modell 1.8, Thermo Scientific (Waltham, MA USA 
16. CO2 incubators 
  innova™ CO-170, New Brunswick Scientific (Nürtingen, Germany) 
  BB15, Thermo Scientific (Waltham, MA USA) 
  Hera Cell 150, Thermo Fischer Scientific (Waltham, MA USA) 
17. ANY-maze video tracking system 
  CM625 camera, Clover Electronics (Newnan, GA USA) 
  DT3120 capture card, Data Translation (Marlboro, MA USA) 
18. Mazes 
  square Open-Field (edge length: 50 cm), non-commercial 
  Y-Maze (WxHxD: 9 cm x 16 cm x 40 cm), non-commercial 
  M-water maze (diameter: 120 cm), non-commercial 
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Antibodies 
A list of all utilized antibodies for immunohistochemistry (IHC) and western blot 
(WB) can be found in Table 1 and Table 2: 
Table 1: Primary antibody specifications 
target manufacturer Cat. # host application dilution / 
concentration 
Iba1 Wako 019-19741 rabbit IHC 1:10,000 
GFAP EnCor RPCA-GFAP rabbit IHC 1:10,000 
HO-1 abcam ab13248 mouse WB 4 µg/mL 
GAPDH abcam ab8245 mouse WB 1:2,000 
β-Actin Santa Cruz sc-47778 mouse WB 1:1,000 
 
Table 2: Secondary antibody specifications 
target manufacturer Cat. # host application conjugation dilution 
mouse 
IgG 
Dako E0354 rabbit IHC biotin 1:400 
rabbit 
IgG 
Dako E0432 goat IHC biotin 1:400 
rabbit 
IgG 
Cell Signaling #7074 goat WB HRP 1:20,000 
goat 
IgG 
Dako E0466 rabbit IHC biotin 1:400 
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Primer 
The following primer pairs were used for qRT-PCR experiments: 
Table 3: qRT-PCR primer pairs 
target species sequence length Tm [°C] 
GAPDH-for mouse AGGTCGGTGTGAACGGATTTG 21 bp 59.8 
GAPDH-rev mouse TGTAGACCATGTAGTTGAGGTCA 23 bp 58.9 
YWHAH-for mouse GAAAAGTTCTTGATCCCCAATGC 23 bp 58.9 
YWHAH-rev mouse TGTGACTGGTCCACAATTCCTT 22 bp 58.4 
SDHA-for mouse GGAACACTCCAAAAACAGACCT 22 bp 58.4 
SDHA-rev mouse CCACCACTGGGTATTGAGTAGAA 23 bp 60.6 
γGCS-for mouse GGGGTGACGAGGTGGAGTA 19 bp 62.3 
γGCS-rev mouse GTTGGGGTTTGTCCTCTCCC 20 bp 62.1 
HO-1-for mouse AAGCCGAGAATGCTGAGTTCA 21 bp 61.7 
HO-1-rev mouse GCCGTGTAGATATGGTACAAGGA 23 bp 61.2 
NQO1-for mouse AGAGAGTGCTCGTAGCAGGAT 21 bp 62.2 
NQO1-rev mouse CTACCCCCAGTGGTGATAGAAA 22 bp 60.6 
TNF-α-for mouse AGGGGCCACCACGCTCTTCT 20 bp 59.8 
TNF-α-rev mouse TGGTTTGCTACGACGTGGGCT 21 bp 58.7 
IL-1 -for mouse AGCCAAGCTTCCTTGTGCAAGTGT 24 bp 59.5 
IL-1β-rev mouse GCTCTCATCAGGACAGCCCAGGT 23 bp 59.9 
IL-6-for mouse TGCAAGAGACTTCCATCCAGTTGCC 25 bp 59.2 
IL-6-rev mouse AAGCCTCCGACTTGTGAAGTGGT 23 bp 58.2 
Ck19-for mouse CGTACCCCCAAAGGAAGACA 20 bp 60.1 
Ck19-rev mouse TCAGACCTGCGTCCCTTTTT 20 bp 60.4 
Coll1a-for mouse GCTACTACCGGGCCGATGATGC 22 bp 65.3 
Coll1a-rev mouse CCTTCGGGGCTGCGGATGTTC 21 bp 65.9 
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Vectors 
The following constructs were used in the course of this thesis. Insert sequences 
for cloning of SIN-lenti-ARE and SIN-lenti-NF--κB are listed in the supplements. 
Table 4: Vector constructs specifications 
name vector company insert transfection 
pGL3-ARE pGL3-promoter Promega ARE transient 
pGL4.17-ARE pGL4.17 Promega ARE stable 
SIN-lenti-ARE SIN-lenti Addgene ARE lentiviral 
pGL3-NF-κB pGL3-promoter Promega NF-κB RE transient 
SIN-lenti-NF-κB SIN-lenti Addgene NF-κB RE lentiviral 
pGL3-AP-1 pGL3-promoter Promega AP-1 RE transient 
phRL-TK phRL-TK Promega  transient 
psPAX2 psPAX2 Addgene  transient 
pMD2.G pMD2.G Addgene  transient 
pLKO.1-shNT pLKO.1 Sigma Aldrich shNonTarget lentiviral 
pLKO.1-shNrf2 pLKO.1 Sigma Aldrich shNrf2 lentiviral 
pLKO.1-shKeap1 pLKO.1 Sigma Aldrich shKeap1 lentiviral 
 
Inserts: 
The NF-κB insert cloned into pGL3-NF-κB refers to a concatenated trimer of the 
wild-type sequence ATGTGGGATTTTCCCATG (the core sequence is underlined). 
Both strands: 
5´-CATGTGGGATTTTCCCATGAGTGAGGGGACTTTCCCAGGCATGTGGGATTTTCCCAT
GG-3' and 5´-CTAGCCATGGGAAAATCCCACATGCCTGGGAAAATCCCCTCACTCATGGG
AAAATCCCACATGGTAC-3'. The AP-1 insert used for pGL3-AP-1 refers to a 
concatenated pentamer of the AP-1 consensus sequence TGAGTCA. The ARE insert 
of pGL3-ARE and pGL4.17-ARE refers to the ARE consensus sequence of the rat 
NQO1 promoter region, as described in 49. The shRNAs were commercially 
available clones from Sigma Aldrich. 
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Cell culture 
All cell culture work was performed under sterile conditions under a standard cell 
culture sterile work bench. 
Cell lines and primary cells 
The following cell lines and primary cells were used in the course of this work: 
Table 5: Cell lines and primary cells 
name cell type species sort reference ATCC 
THP-1 monocyte Homo sapiens cell line TIB-202 
RAW 264.7 macrophage Mus musculus cell line TIB-71 
BMDM macrophage Mus musculus primary  
L-929 fibroblast Mus musculus cell line CCL-1 ™ 
HEK 293T embryonic 
kidney cell 
Homo sapiens cell line CRL-1573™ 
HSE synoviocyte Homo sapiens cell line  
K4IM synoviocyte Homo sapiens cell line  
The cell line HSE was obtained from Oligene (Berlin, Germany) and the 
immortalized K4IM cells were a kind gift from Christian Kaps (Charité, Berlin, 
Germany). All other cell lines were purchased from LGC Standard / ATCC Europe 
(Wesel, Germany). 
Culture conditions 
If not otherwise mentioned, all cells were cultured in 75 cm² culture flasks 
(Sarstedt, Nuembrecht; Germany) at 37°C, 70 – 80 % humidity and 5 % CO2. For 
standard sub culturing all media were supplemented with 2 mM glutamine, 10 % 
fetal calf serum (FCS) and 1 % penicillin/streptomycin (PeSt). A detailed list of 
adequate base media for different cell types can be found in Table 6.
MATERIALS & METHODS 
32 
Table 6: Cell culture base media 
cells base medium 
THP-1 RPMI 1640 
RAW264.7 DMEM High Glucose 
BMDM RPMI 1640 
L-929 MEM 
HEK 293T DMEM 
HSE RPMI 1640 
K4IM RPMI 1640 
 
L-929 culture medium (LCM) production and harvest 
LCM is the cell culture supernatant of serum-deprived L-929 fibroblasts and 
constitutes an essential compound for the differentiation of bone marrow derived 
macrophages. To obtain this supernatant, L-929 cells were cultured and expanded 
in 75 cm² culture flasks with L-929 medium 1. Once the cells reached 90 % 
confluency they were transferred to 175 cm² culture flasks, cultured in 50 mL L-
929 medium 2 for 48h. After 48h the medium was harvested. Cells were again 
supplemented with 50 mL L-929 medium 2, followed by a second medium 
collection after 48h. The gained cell culture supernatants were centrifuged for 
5 min at 250 x g to separate cells and debris from the medium. Subsequently the 
supernatant was filtered through a 45 µm sterile filter to ensure sterility. LCM was 
stored at -20°C until use. 
L-920 medium 1 L-929 medium 2 
Eagle’s MEM Eagle’s MEM 
+ 10 % FCS + 5 % FCS 
+ 1 % PeSt + 1 % PeSt 
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Isolation and differentiation of bone marrow derived macrophages (BMDM) 
Primary bone marrow derived macrophages (BMDM) were isolated from mouse 
femora and tibia bone marrow. Therefore, the mice were euthanatized by cervical 
dislocation. Afterwards, the femora and tibia of both limbs were dissected and 
extraneous tissue was removed using sterile scissors and gauze swabs. Clean and 
intact bones were stored in 70 % ethanol and handled under sterile conditions 
using a sterile work bench. Epiphyses were removed with the help of a sharp 
scalpel and the remaining diaphyses were transferred into ice-cold R-10 medium. 
To obtain the bone marrow, the diaphyses were flushed with 20 mL of ice-cold R-
10 medium using a 23 gauge needle adapted to a 20 mL syringe. The bone tissue 
was discarded and the R-10 medium containing isolated bone marrow cells was 
centrifuged for 5 min at 250 x g. Bone marrow plug was resuspended in 2 mL 
pre-warmed R-10 LCM20 medium and seeded in a 15 cm non-tissue petri dish 
filled with 23 mL R-10 LCM20 medium. After 72h at 37°C and 5 % CO2, the cells 
were fed by adding 15 mL R-10 LCM20 medium. At day 6 the medium was 
replaced by fresh R-10 LCM20 and all non-adherent cells were discarded. 24h later 
the cells were ready to use for experimental procedures. 
R-10 medium R-10 LCM20 medium 
RPMI 1640 RPMI 1640 
+ 10 % FCS + 10 % FCS 
+ 1 % PeSt + 1 % PeSt 
 + 20 % LCM 
Serum deprivation of cell lines 
One week before stimulation experiments of cell lines were conducted, a 
sequential serum deprivation was performed. Therefore, the cells were cultured 
with gradually reducing FCS content from initially 10 %, followed by two days with 
7.5 %, two days with 5 %, one day with 3 %, one day with 2 % and one day with 
1 % FCS. The final concentration of FCS during stimulation was 1 %. 
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Transient/Stable DNA insertion by transfection 
Transfection approaches were performed with jetPRIME™ transfection kit 
(PolyPlus transfection, Illkirch Cedex; France) in 6-well micro titer plates as 
recommended by the manufacturer. Cell culture medium was replaced 6h after 
transfection. In the case of transient transfected constructs, the cells were used 
48h after transfection for following analysis. Stable transfected cells were 
incubated with normal growth medium for 48h, before selection antibiotics were 
supplemented. In parallel, untransfected control cells were also grown under 
selective pressure. Stable cell lines were established when all cells in the 
untransfected negative control flask were killed while the transfected cells further 
survived. All applied vectors are listed in Table 4. 
Production of lentiviral particles 
All virologic working was conducted according to current legal law and regulations 
of the Central Committee for Biological Safety and the Federal Office of Consumer 
Protection and Food Safety. All working steps with virologic material were done in 
the S2-laboratories of the Institute of Pharmacology and Toxicology in Prof. Dr. 
Ludwig’s work group. 
Within the scope of this study, a second generation plasmid system was used to 
produce lentiviral particles. Therefore, a combination of three plasmids was co-
transfected into the cell line to produce lentiviral particles. This second generation 
plasmid system comprises the following vectors (Table 4): 
• a lentiviral transfer-vector, containing the gene of interest  
(e.g. pLKO.1 for shRNA expression; SIN-lenti for reporter gene expression) 
• a packaging vector (e.g. psPAX2) 
• a vector, encoding the envelope protein (e.g. pMD2.G) 
Nrf2 and Keap1 knock-down was achieved by lentiviral delivery of specific shRNAs 
from the Sigma Aldrich Mission® shRNA library. All shRNA clones were expressed 
by the pLKO.1 vector system. As luciferase based reporter gene backbone 
construct the SIN-lenti vector was used. The response elements for Nrf2 activity 
(ARE) and NF-κB activity (NF-κB RE) were cloned into the multiple cloning site. 
Viral particles were produced in HEK 293T cells. These cells originate from human 
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embryonic kidney cells and stably express the SV40 T antigen resulting in a highly 
increased expression of all proteins encoded on the vectors, which are under the 
control of a SV40 replication origin. Transfection was performed using the jetPEI 
reagent from peqlab (Erlangen; Germany) as it is described to be very efficient for 
the production of high viral titers. The transfection mix was applied as 
recommended by the manufacturer. After being exposed to the transfection mix for 
12h, cells were washed with pre-warmed PBS and fresh culture medium was 
added. Viral particles were harvested 48h later. Therefore, the virus-containing 
cell culture supernatant was collected, centrifuged for 10 min at 500 x g and 
sterilized with the help of a sterile filter (pore size: 0,45 µm). The lentiviral 
supernatant was either directly aliquoted and stored at -70°C or further enriched 
by ultra-centrifugation using 23 mL of the cleaned supernatant which was 
centrifuged for 2h at 24.000 rpm in a SW28 rotor containing cold Beckmann 
centrifuge. After centrifugation the supernatant was carefully removed, the pellet 
was resuspended in 1000 µL ice-cold PBS, aliquoted and stored at -70°C.  
Determination of virus titer level 
To determine the viral titer of the supernatants or the enriched suspension, 
HEK293T cells were transduced with a GFP (green fluorescent protein) containing 
control vector. For the detection of positive transduced cells and subsequent 
calculation of titers, flow-cytometry was used. Therefore, 5 * 104 cells per well 
were plated in a 24-well plate. The culture medium additionally contained 
8 µg/mL Polybrene® to increase transduction efficiency. Before cell adherence, the 
viral supernatants respectively the enriched viral suspensions were added in 
various dilutions (undiluted, 1:3, 1:9, 1:27, 1:81, and 1:243). After 16h the cells 
were washed with pre-warmed PBS and medium was refreshed. 72h later, the cells 
were trypsinized, washed with PBS, resuspended and fixed with paraformaldehyde 
(PFA) for the following flow cytometry analysis. 
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GFP positive cells were determined for each sample and the number of infectious 
particles was quantified from the dilution with approximately 1 to 10 % GFP-
positive cells (see equation 1): 
 FV
ZAL)titer(TU/m ∗




 ∗
=  (equation 1) 
TU = transduction units 
A = amount of GFP-positive cells 
Z = cell count at time of infection 
V = volume of supernatant in the well 
F = dilution factor 
Transduction 
Transduction of target cells was performed with the viral supernatant or the 
enriched suspension. Therefore, 5 * 105 cells were seeded in one well of a 6-well 
plate. The amount of infectious particles, called multiplicity of infection (MOI) was 
held stable over all experiments. The MOI is calculated from the previously 
determined titer and the used cell count (see equation 2). 
 cellTUMOI /=  (equation 2) 
Virus content with a MOI of 10 and 8 µg/mL Polybrene® (hexamethrin bromide) 
were added to the cells before they were able to adhere. Polybrene® is a cationic 
polymer, which enhances the transduction efficiency by neutralizing charge 
repulsion between the virion and the siliac acid of the surface, promoting the 
uptake of the virion by endocytosis. The cells were transduced for 16h, afterwards, 
they were washed with PBS and cell culture medium was replaced. Stable 
expression of shRNAs and separation of untransduced cells was ensured by 
selective pressure due to puromycin addition to the cell culture medium. 
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Stimulation protocols 
Stimulation of HSE 
• Luminometer assay  
After transient transfection of reporter gene constructs, HSE cells were 
seeded in a 96-well micro titer plate and were left to adhere overnight. 
Subsequently, the cells were pre-treated with 10 ng/mL TNF-α for 3h to 
induce pro-inflammatory conditions. Afterwards, the cells were stimulated 
with 6.25 µM sulforaphane for further 6h. Cells were lysed in passive lysis 
buffer PLB (Promega, Madison; WI USA) as recommended by the 
manufacturer to obtain samples for luminometer measurements. 
• Real-time cell analysis (xCELLigence RTCA) 
Gene silencing was conducted via lentiviral shRNA delivery as described 
above. For this experiment a pLKO.1 shRNA construct directed against 
Keap1 (MISSION® shRNA assortment, Sigma Aldrich, Germany) was used. 
To exclude variations due to the vector backbone and to prove that the 
effects are exclusively dependent on the shRNA, transduction of HSE cells 
with a shNonTarget control construct was performed. For the RTCA 
experiment 5*104 cells were seeded per well in the RTCA E-Plate and were 
stimulated with TNF-α (for more details on RTCA see methods section 
xCELLigence RTCA). 
Stimulation of THP-1, RAW 264.7 and BMDM 
• Stimulation with pro-inflammatory stimuli (cytokines & PAMPs) 
All immune cells were stimulated for various durations (15min, 30min, 1h, 
3h, 6h, 12h, 24h) with a couple of pro-inflammatory cytokines and 
pathogen-associated molecular patterns (PAMPs), which are depicted in 
Table 7. 
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Table 7: Recombinant proteins for stimulation experiments 
name molecule  concentration manufacturer 
TNF-α pro-inflammatory cytokine 10 ng/mL Peprotech 
IL-1β pro-inflammatory cytokine 10 ng/mL Peprotech 
IL-6 pro-inflammatory cytokine 10 ng/mL Peprotech 
TWEAK pro-inflammatory cytokine 100 ng/mL Peprotech 
IFN-γ pro-inflammatory cytokine 10 ng/mL Peprotech 
IL-4 anti-inflammatory cytokine 10 ng/mL Peprotech 
IL-10 anti-inflammatory cytokine 10 ng/mL Peprotech 
LPS PAMP 100 ng/mL Sigma Aldrich 
PGN PAMP 10 ng/mL Peprotech 
M-CSF chemokine 20 ng/mL Peprotech 
After the stimulation, cells were washed with PBS once and lysed in an 
appropriate lysis buffer afterwards (luminometer assay: PLB; RNA 
isolation: RA1 from RNA Extract II kit, Macherey Nagel). 
Inhibitor/Antioxidant assay 
RAW264.7 cells were stimulated for 12h with 10 ng/mL TNF-α. 30 min prior to 
stimulation the cells were pre-treated with different kinase inhibitors (Table 8) or 
antioxidants (Table 9) to examine kinase or ROS involvement in the underlying 
signal cascade. 
Table 8: Kinase inhibitors 
name target concentration manufacturer 
U0126 MEK 1/2 10 µM Cell Signaling 
PD98059 ERK 1 20 µM Calbiochem 
SB203580 p38 MAPK 5 µM Calbiochem 
Wortmannin PI3K 1 µM Calbiochem 
SP600125 JNK 2 µM Calbiochem 
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Table 9 Antioxidants and NOX inhibitors 
name function concentration manufacturer 
GME ROS scavenger 2 mM Calbiochem 
N-Acetyl-Cysteine ROS scavenger 5 µM Sigma Aldrich 
DTT ROS scavenger 10 µM Sigma Aldrich 
DPI NOX inhibitor 1 µM Sigma Aldrich 
apocynin NOX inhibitor 100 µM Sigma Aldrich 
gp91-ds-tat NOX inhibitor 50 µM Anaspec 
After the stimulation, cells were washed with PBS once and lysed in Passive 
Lysis Buffer (Promega, Madison; WI USA. 
• LPS tolerance 
RAW264.7 and BMDM were used for LPS tolerance experiments. Cells were 
either pre-treated with 100 ng/mL LPS for 24h or untreated prior to LPS 
stimulation for 4h. Completely untreated cells dealt as controls. 
Supernatants were collected for Luminex LiquiChip assay and cells were 
lysed for either luminometer assay or qRT-PCR experiments. 
xCELLigence RTCA 
To analyze the effect of Nrf2 expression during TNF-α stimulation on proliferation 
of HSE cells a continuous real-time impedance measurements using the 
xCELLigence system (Roche Diagnostics, Mannheim, Germany) was conducted. The 
xCELLigence system is based on a 96-well cell culture plate with a microelectrode 
array in the bottom of each well (E-Plate). Measurement of electrode impedance of 
the separate wells can be done in defined intervals. For analysis the impedance is 
converted to a dimensionless parameter named Cell Index (CI). The CI is zero 
without cell adherence and increases when cells attach or proliferate on the 
microelectrode surface. For background subtraction, all wells of the E-Plate were 
filled with 200 µL of growth medium and background impedance was measured 
before stimulations took place. Afterwards, 5 * 103 HSE cells stable expressing a 
shRNA targeting Keap1 or a nonTarget control shRNA were seeded per well by 
replacing 100 µL of the total medium. Subsequent impedance measurements were 
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conducted every 20 minutes under normal cell culture conditions. After an 
overnight adherence phase cells either got TNF-α in a final concentration of 
10 ng/mL by replacing 100 µL fresh medium per well, whereas control cells 
received equal amounts of fresh medium without TNF-α. The experiment was 
continued for further 24h and the CI was normalized to the time point, when TNF-
α was added afterwards. Analysis was conducted with RTCA software 1.2.1 (Roche 
Diagnostics, Mannheim, Germany). 
Animals 
All animals used in this study maintained in our animal facility under a 12h light-
dark cycle (light on at 7:00 h), controlled room temperature (22 ± 2°C) and specific 
pathogen-free conditions. If not otherwise mentioned, mice were given access to 
standard rodent diet and tap water ad libitum. The experiments were conducted in 
accordance with the German animal protection law and were approved by regional 
governmental authorities. 
Strains 
Nrf2 wild type/knockout mice with C57BL/6 background were kindly provided by 
Professor Yuet Wai Kan (Howard Hughes Medical Institute and Cardiovascular 
Research Institute, University of California, USA). The mating of these animals was 
kept heterozygous to obtain wild type as well as knockout littermates. 
Cre transgenic animals are widely used to get conditional knockout strains. The cre 
recombinase is able to delete DNA sequences flanked by loxP sites. 
Keap1ΔVaV-iCre-KO mice were obtained by cross-breeding of transgenic animals 
containing loxP flanked Keap1 alleles (kind gift from Prof. Thomas W. Kensler; 
Department of Pharmacology and Molecular Sciences, School of Medicine, Johns 
Hopkins University, 615 North Wolfe Street, Baltimore, MD21205, USA) and 
transgenic animals expressing an improved cre recombinase 47 which is under the 
control of the vav1 gene regulatory elements (The Jackson Laboratory: 
B6.Cg-Tg(Vav1-cre)A2Kio/J, Stock #: 008610) 44. The resultant Keap1ΔVaV-iCre-KO 
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animals exhibit the knockdown in all hematopoietic cells (and their progenitors) 
including the hematopoietic progenitor-rich bone marrow. 
The antioxidant response element (ARE) containing luciferase (luc) reporter gene 
mice C57Bl6/J(ARE-luc) were purchased from Cgene (Oslo, Norway). 
The animals used for behavioral testing were adult mice in the age of 52 weeks of 
the C57BL/6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/J strain (APP/Psen1). 
These mice were purchased from The Jackson Laboratory (Jax stock No.: 005866). 
Animal models 
1. Alzheimer’s disease (AD) mouse model 
Investigation on the pathology of Alzheimer’s disease was conducted with the 
transgenic APP/Psen1 mouse strain. These animals carry two human mutations 
(amyloid precursor protein APP; presenilin 1 Psen1), which are highly associated 
to the genetically induced onset of AD. These two mutations are known to be 
responsible for a misleaded cleavage of APP, which in turn leads to the formation 
of aggregates also called amyloid-beta (Aβ) plaques. These depositions are known 
to be harmful for the surrounding tissue due to increased oxidative stress, 
astrogliosis and microglia infiltration (neuroinflammation) leading to excessive 
neurodegeneration with severe cognitive deficits in the end. These were either left 
untreated or were treated with methysticin 27 weeks before euthanasia. All 
animals were sacrificed in the age of 52 weeks. 
Methysticin treatment strategy: 
Methysticin is a biomolecule originating from the plant Kava Kava (lat. Piper 
methysticium). It belongs to the bioactive molecule group called kavalactones, 
which are able to induce the Nrf2/ARE system due to its electrophilic properties. 
Methysticin was obtained from LKT laboratories Inc. (St. Paul; MN, USA) and 
administered generally by oral gavage. As proof-of-principle approach 
ARE-luciferase reporter gene mice were short-term treated with methysticin. 
The mice were given 6 mg/kg bodyweight methysticin at three consecutive days. 
After the third treatment the mice’s hippocampus, cortex, midbrain, and 
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cerebellum tissue was separated as described in the following and immediately 
snap-frozen in liquid nitrogen. In transgenic APP/Psen1 mice (n = 6) 
administration began at 25 weeks and lasted for 27 weeks. The animals were 
treated once per week with 6 mg/kg bodyweight methysticin. At 52 weeks, the 
animals underwent behavioral testing and were euthanized afterwards. The 
brain tissue was formalin-fixed for paraffin embedding. 
 
Fig. 4 Timeline for methysticin treatment of APP/Psen1 mice. Treatment started when animals reached the age of 
25 weeks. From then they received 6 mg/kg bodyweight (BW) methysticin once a week by oral gavage. Treatment 
ended with an age of 52 weeks. At that moment all animals were passed through the behavioral tests (Open-Field, 
Y-Maze and Morris-Water Maze) and were euthanatized afterwards. 
2. Sclerosing cholangitis model 
Cholangitis was induced in Nrf2-WT and Nrf2-KO mice by feeding them with a 
0.1 % 3,5-diethoxycarbonyl-1,4-dihydrocolidine (DDC) diet. DDC and standard 
food in control animals was given in powder form for a duration of 4 weeks. DDC 
feeding leads to a sclerosing cholangitis with severe ductular reactions, 
bilirubinostasis, apoptosis, necrosis, inflammation and increased proliferation of 
cholangiocytes. 
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Behavioral tests 
30 minutes before behavioral testing, the mice were brought to the laboratory in 
their home cages in order to let them adapt to their new environment. The 
temperature was held stable at 22±2°C, and the room was slightly illuminated. 
Open-Field 
The mice’s locomotion, anxiety, and exploratory behavior were investigated with 
an open field apparatus (Fig. 26A, WxHxD: 50 cm x 50 cm x 50 cm). 
 
Fig. 5 Schematic illustration of the Open-Field set-up 
All animals underwent this test once. For this purpose, they were placed in the 
center of the maze and given ten minutes to freely explore it. The animals were 
tracked with a Stoelting Co. ANY-maze™ video tracking system and software 
(Wood Dale, Illinois, USA); data were collected concerning mean speed, absolute 
and relative time spent in different zones (corners, sides and center) of the maze, 
and the total distance each animal traveled during the experiment. 
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Y-Maze 
To test the animals’ working memory a Y-Maze with three identical arms (Fig. 6, 
WxHxD: 9 cm x 16 cm x 40 cm) arrayed at 120° angles was used. 
 
Fig. 6 Schematic illustration of the Y-maze set-up 
The floor and walls were painted white to provide maximal contrast to the 
animals’ color to ensure best tracking quality. All animals underwent this test once. 
To start the test, the animal was placed in the lower arm of the maze (C) and was 
given six minutes to freely explore it. Each mouse’s mean speed, total distance 
traveled, and the order in which it visited each arm were monitored and analyzed 
with Stoelting Co. ANY-maze™ video tracking system and software (Wood Dale, 
Illinois, USA). For statistical analysis, the spontaneous alteration (SA %) of arm 
visits was calculated as depicted in equation 3.  
100)2(% ∗


 −
=
salteration
stotalvisitSA
   (equation 3) 
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Morris Water Maze 
To assess the animals’ long-term memory performance, a circular Morris water 
maze (diameter 120 cm; height 50 cm) was used. The maze was filled with white-
stained pre-warmed (22±2°C) water to provide maximal contrast to the animals’ 
skin. 
 
Fig. 7 Schematic illustration of the Morris water maze set-up 
The maze was divided into four quadrants, equipped with 4 landmarks (Fig. 7: Δ, ⎕, 
X, O) at the inside of the wall. The white escape platform (diameter 10 cm; height 
24 cm) was located 1 cm below the water surface at 4 possible platform positions 
(Fig. 7) during the flagged/training trials and at a fixed position during test trials 
(platform position 1). The tests took place each day for a time period of 5 days, 
with 6 trials held each day (3 trials in the morning and 3 trials in the afternoon). 
The three contiguous trials were held at 5 min intervals, and the morning and 
afternoon sessions were separated by a 5-hour break. The tests were grouped into 
three stages: flagged trials (day 1 and 2, trial 1-12), training trials (day 3 and 4, 
trial 1-12), and test trials (day 5, trial 13-18). For the flagged trials the platform 
position was clearly indicated by a black flag and the landmarks were removed 
from the maze. In these trials the animals were inserted at the position between O 
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and Δ, and the platform position was alternated in every trial. For the training 
sessions, the flag was removed and the animals were inserted at different starting 
points with a constant platform position. In the test trials, all animals started 
between O and Δ, and the platform was sited at position 1. In each trial, mice were 
placed at one of the distinct places, faced to the wall, and were allowed to swim 
freely until they reached the hidden platform. Mice, which failed to find the 
platform within 60 seconds, were placed on the platform for 10 seconds (equal 
time as successful animals stay on it). Floating mice were eliminated from analysis. 
ANY-maze™ was used to track the animals during the test; data were collected 
according to their latency (or time taken to find the platform), average swimming 
speed, and covered distance, and for track plots. These data were used to analyze 
the mice’s learning abilities. 
Tissue preparation 
Liver tissue preparations were conducted fast and accurate on ice to avoid sample 
degradation. Animals were sacrificed by cervical dislocation. Immediately 
afterwards the abdominal cavity was opened to get access to the liver. Tissue 
specimens were divided into two parts. Fresh tissue was collected and directly 
snap-frozen for subsequent nucleic acid analysis or proteomics. The other part of 
tissue was formalin fixed for following histology and immunohistochemistry (see 
section Histology/Immunohistochemistry). Preparation procedure of brain tissue 
varied from this and is described in more detail below. 
Transcardial perfusion 
To retain high quality brain tissue specimen, the animals were transcardially 
perfused with ice-cold artificial cerebrospinal fluid (ACSF). Therefore, the animals 
were anaesthetized with a ketamine/xylazine cocktail. Ketamin was injected 
intraperitoneally at a dose of 100 mg/kg bodyweight and xylazine at a dose of 
10 mg/kg bodyweight. As soon as the surgical tolerance was reached, the mice 
were dissected. Therefore, the abdominal cavity was opened to get access to the 
thoracic cavity and the heart. Perfusion was initiated into the left ventricle to 
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perfuse the systemic circulation. The right atrium was opened to enable the 
perfusate fluid to flow out. 
Dissection of brain areas 
After transcardial perfusion mice were decapitated rostral to the first cervical 
vertebra and brain tissue was obtained as follows. The cranial vault was carefully 
opened with scissors without damaging the underlying brain tissue. Then the 
occipital, parietal skull plates were separated. The dura mater was carefully 
removed before the temporal skull plates were removed to prevent tissue damage. 
Afterwards the brain was removed as a whole and placed in “slushy” ACSF 
(artificial cerebrospinal fluid) for at least 1 min. All consecutive steps were 
performed on ACSF-soaked Whatman filter lying on an ice-cold petri-dish. The two 
hemispheres were separated by gently cutting through the intrahemispheric 
fissure. One hemisphere was formalin fixed, the other further processed. 
Cerebellum and approximately one quarter of the rostral frontal lobes were 
removed with a scalpel blade. Midbrain, brain stem and thalamus were hold at 
place with surgical scissors. A spatula was used to slide into the gap between the 
colliculi on the midbrain and the neocortex. Further sliding into this gap and 
concurrently pulling away the brainstem/midbrain/thalamus revealed the inside 
of the lateral ventricle and the medial surface of the hippocampus. A spatula was 
used to slide into the gap between the hippocampus and the underlying cortical 
tissue. In this way the hippocampus was rolled off and afterwards separated from 
the neocortex. 
ACSF 
220 mM sucrose 26 mM NaHCO3 
10 mM glucose 3 mM KCl 
2,6 mM MgSO4 1,25 mM NaH2PO4 
MATERIALS & METHODS 
48 
Nucleic acid analysis 
Cloning of SIN-lenti-ARE & SIN-lenti-NF-κB 
The SIN-lenti vector is a reporter gene construct which is suitable for lentiviral 
transduction. As reporter the vector contains the firefly luciferase gene from 
Photinus pyralis. The vector was obtained as SIN-lenti-7TFP from addgene 
(Cambridge; MA USA) incl. TCF response elements. These elements were removed 
by restriction (NheI & PstI), so that the desired ARE respectively NF-κB inserts 
(described below) could be cloned in. The vector contains a minimal promoter 
directly behind the cloned response elements, whereby following luciferase 
transcription is under the control of the investigated transcription factors (Nrf2 or 
NF-κB, respectively). Ligation, transformation of E. coli and subsequent DNA 
isolation was performed as described in the following chapters. The obtained 
SIN-lenti-ARE and SIN-lenti-NF-κB clones were sequenced to verify correct 
sequences. 
Annealing of complementary ssDNA molecules 
ARE and NF-κB inserts for the following cloning into the reporter gene vector SIN-
lenti were obtained by annealing complementary ssDNA oligos. The ssDNA oligos 
were synthesized by MWG Eurofins (Ebersberg, Germany) and designed to form 
sticky ends suitable for ligation with PstI and NheI restricted plasmid DNA. 
Complete ssDNA sequences are found in the supplements. Annealing was 
performed in a total volume of 12.5 µL hybridization buffer. To obtain optimal 
hybridization conditions, the approach was heated to 95°C in a PCR cycler for 3 
min and afterwards the cycler was turned off, so the temperature slowly reduces 
to RT. Thus, the optimal annealing temperature was necessarily passed through at 
some point. 
Restriction of plasmid DNA 
SIN-lenti plasmid DNA was restricted for cloning approaches of ARE and NF-κB 
inserts. Therefore, 10 µg of plasmid DNA was used in a total reaction volume of 
25 µL. The restriction enzymes PstI and NheI (New England Biolabs, Ipswich; MA 
USA) were applied with 3 U per µg plasmid. The restriction was conducted at 37°C 
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for 1.5h in NEBuffer 2.1 as recommended by the manufacturer. After restriction, 
the enzymes were heat inactivated at 65°C for 20 min. Sufficient restriction was 
validated by agarose gel electrophoresis. 
Agarose gel electrophoresis 
Electrophoretic separation of restricted DNA fragments was conducted with 1 % 
TAE buffered agarose gels. Fragment sizes were verified with the help of 100bp 
GeneRuler™ DNA ladder from Thermo Scientific (Waltham; MA USA). For the 
detection of DNA, ethidium bromide was added to the agarose gel and UV light was 
used for visualization. All DNA samples were prepared with loading buffer and 
then applied to the agarose gel. Electrophoresis was conducted at 120 V constant 
for 40 min. 
 50x TAE buffer 6x loading buffer 
 242 g Tris 5 % glycerol 
 57.1 mL acetic acid bromophenol blue 
 100 mL 0.5 M EDTA pH 8.0 
 Ad 1 L aqua dest. 
Ligation of DNA 
Integration of the ARE/NF-κB inserts into the multiple cloning site of the SIN-lenti 
vector was conducted via ligation of the dsDNA inserts and the previously 
restricted SIN-lenti construct. The molar vector-insert-ratio was set to 1:3. The 
ligation took place in a total volume of 20 µL with 0.1 U T4 ligase (invitrogen, 
Carlsbad; CA USA) and the appropriate ligation buffer system recommended by 
the manufacturer. Ligation was conducted at 26°C for 1h. 
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Transformation of E. coli 
Transformation was conducted with chemically competent E. coli OneShot Top10, 
commercially available from life technologies (Carlsbad; CA USA). 
genotype of E. coli OneShot Top10:  F-mcrA, _(mrr-hsdRMS-mcrBC),  
  φ80lacZ_M15, _lacX74, nupG, recA1,  
  araD139_(ara-leu)7697, galE15, galK16,  
  rpsL(StrR), endA1, λ- 
25 µL of these cells were used for each transformation approach. Therefore the 
bacteria were thawed on ice and 0,5 µL of the ligation sample was added. The 
mixture was left on ice for 30 minutes. Afterwards the bacteria were exposed to a 
heat shock (42°C) for 20 seconds. After the addition of 250 µL SOC medium, the 
bacteria were incubated at 37°C and 800 rpm for 45 minutes. Finally 170 µL of the 
suspension was plated on LB-agar plates including antibiotics for selection. These 
plates were incubated at 37°C for 12 hours. The next day colonies were picked to 
inoculate 10 mL LB-broth incl. antibiotics to gain fluid cultures (preculture). Eight 
hours later 1 mL of the preculture was used to inoculate a 300 mL fluid culture. 
Isolation of plasmid DNA from E. coli 
Amplified plasmid DNA was isolated from E. coli fluid cultures with the help of the 
NucleoBond® Xtra Midi/Maxi Plus Kit (Macherey Nagel, Düren, Germany). 
Therefore, transformed E. coli were plated on LB-agar plates including appropriate 
selection antibiotic (ampicillin 100 µg/mL) and incubated overnight (at least 10h) 
at 37°C. Single-cell colonies were picked at the next day to inoculate 10 mL 
LB-broth including selection antibiotic. This pre-culture was incubated for further 
10h at 37°C. One mL of the pre-culture was used to inoculate the main culture 
(300 mL LB-broth incl. ampicillin). E. coli were harvested the next day as described 
in the kit manual.  
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Sequencing of DNA 
DNA sequencing was done by MWG Eurofins (Ebersberg, Germany). The vectors 
and the appropriate sequencing primers were forwarded as recommended by 
MWG. 
RNA isolation and quality control (QC) 
The entire work with RNA material was conducted under special diligence and 
exclusion of RNAse activity. Total RNA was extracted from 8 x 105 cells 
(RAW 264.7) or 30 mg tissue (liver) using the RNA Extract II kit (Macherey-Nagel 
GmbH & Co. KG, Düren, Germany) according to the manufacturer’s instructions. 
Total RNA amount and purity was determined with the NanoDrop 1000 system 
(peqlab, Erlangen; Germany). RNA integrity was controlled by MOPS buffered 
agarose gelelectrophoresis. For that purpose the RNA samples were prepared with 
2x RNA loading dye (Thermo Scientific, Waltham; MA USA) and heated to 70°C for 
10 min. Gel electrophoresis was conducted with 6 V/cm² gel length for 40 min. 
Band densities of 28S and 18S ribosomal RNA were analyzed with Quantity One 
4.6 (BioRad, Hercules; CA USA) and the 28S/18S ratio was calculated to get an 
impression of RNA integrity. 
 10x MOPS Buffer (pH 7.0) 
 - 0.2 M morpholinopropanesulphonic acid (MOPS) 
 - 50 mM sodium acetate 
 - 5 mM EDTA 
cDNA synthesis 
Reverse transcription was performed using the Superscript® VILO™ cDNA 
synthesis kit (life technologies, Carlsbad; CA USA) as described by the 
manufacturer. This kit includes random hexamers for RNA priming. For every 
sample at least 1.5 µg of total RNA was reverse transcribed. 
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Primer design 
All primers were designed with the integrated Primer-BLAST tool found on the 
NCBI web presence. Search parameters were limited as follows: 
• PCR product size: 70 – 250 bp 
• Primer Tm: 57 – 63°C (optimal 60°C) 
• Primer spanning exon junctions were preferred 
• Separation of primers by at least one intron 
• Specificity check for investigated species 
The suggested primer pairs were further analyzed concerning their tendency to 
form secondary structures with mfold (http://mfold.rit.albany.edu/?q=mfold) and 
to form hetero- and homo-dimers with OligoAnalyzer 3.1 from Integrated DNA 
Technologies (IDT, Leuven, Belgium). PCR product length and melting temperature 
was calculated with the online BioMath Tm calculator for oligos (Promega, 
Madison, WI USA). 
qRT-PCR and quality control (QC) 
Relative qRT-PCR was performed with the StepOne Plus real-time PCR system 
(Applied Biosystems as part of life technologies, Carlsbad; CA USA) using SYBR 
Green I technology. Power SYBR® Green PCR Master Mix was also obtained from 
Applied Biosystems. Optimal annealing temperatures of specific primers were 
established in previous runs. All samples were analyzed in technical triplicates. 
After an initial denaturation step (10 min at 95°C), the PCR was run for 40 cycles 
(95°C for 15 sec, specific annealing temperature for 30 sec, elongation at 72°C for 
60 sec). Suitable reference genes for normalization of target gene expression were 
established using GeNorm® calculations 50. Target gene expression in the liver was 
therefore normalized against succinate dehydrogenase complex subunit A (Sdha) 
and glyceraldehyde 3-phosphate dehydrogenase (Gapdh) after establishing these 
genes as the most stable and proper reference genes after DDC treatment. 
Normalization of gene expression in macrophages after TNF-α stimulation was 
conducted with Sdha and tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, eta polypeptide (Ywhah). Gene expression 
levels were efficiency-corrected as described by Pfaffl 51. Amplification efficiencies 
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were determined by LinRegPCR 12.4 software (Heart Failure Research Center, 
Academic Medical Centre, Amsterdam, the Netherlands) 52. Analysis and quality 
control of the qRT-PCR runs were conducted with StepOne Plus 2.2 software 
(Applied Biosystems, Darmstadt, Germany) for further data analysis qBase Plus 2.6 
software (Biogazelle, Zwijnaarde, Belgium) was used. 
MIQE guidelines conformance 
The entire qRT-PCR study was planned and conducted conforming to the 
requirements of the MIQE guidelines 53, as long as the necessary hardware existed. 
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Proteomics 
Protein isolation from cells and tissue 
For subsequent protein analysis by western blot, protein content had to be isolated 
from cells respectively tissue. For that purpose proteins were extracted with RIPA 
buffer to get total protein from the starting material. Before lysis, protease 
inhibitor cocktail (Roche, Basel; Switzerland) was added freshly to the RIPA buffer 
to obtain the working solution. Samples of RAW264.7 macrophages were prepared 
by removing the supernatant and washing the cells once with ice-cold PBS on ice. 
Subsequently, ice-cold RIPA buffer was added to the monolayer and cells were 
detached from plastics and lysed with a standard cell scraper. Lysates were 
transferred into 1.5 mL tubes and shaken at 4°C for 30 min for ongoing lysis. Cell 
debris was removed by centrifugation for 20 min at 4°C and 15,000 x g. Pellets 
were discarded and the supernatant gained for further analysis. Samples of snap-
frozen livers (approx. 30 mg) were thoroughly chopped on dry ice first. The small 
tissue pieces were then homogenized in RIPA buffer (300 mL/5 mg tissue), 
transferred to 1.5 mL tubes and shaken for 2h at 4°C. Centrifugation was 
conducted as described for cell lysates and supernatants were used as total protein 
samples. 
 RIPA buffer pH 8.0 
 150 mM sodium chloride 
 1 % NP-40 (v/v) 
 0.5 % sodium deoxycholate (w/v) 
 0.1 % sodium dodecylsulphate (w/v) 
 50 mM Tris 
Bicinchoninic acid (BCA) assay for protein quantification 
The BCA assay was conducted as recommended by the manufacturer (Thermo 
Scientific, Waltham; MA USA). Minor modifications were introduced regarding 
applied sample and reagent volumes. The BCA working solution was prepared as 
demanded and analysis took place in a 96-well micro titer plate. Therefore, 10 µL 
of the sample or the standard were pipetted. Subsequently, 200 µL of the prepared 
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working solution was added to each well and the plate was incubated for 30 min at 
37°C. Absorbance was read out in a 96-well plate reader with an excitation of 
562 nm. The conversion of raw data to final concentration was facilitated by a 
standard curve from BSA protein standards with known concentrations supplied 
in the kit. 
Western Blot analysis 
SDS-polyacrylamide-gel electrophoresis 
Separation of protein samples was conducted by a sodium dodecyl sulfate-
polyacrylamide-gel electrophoresis (SDS-PAGE). SDS exhibits a highly negative 
charge and is primarily used in the SDS-PAGE to denaturate the proteins and to 
superpose their net charge. SDS transfers a consistent charge on the proteins, so 
that all proteins get negatively charged after this treatment. Furthermore, the 
accumulation of SDS results in a dissociation of non-covalent bonds within the 
tertiary and quaternary protein structure. Thus, protein separation takes place 
independently of net charges, but only corresponding to their molecular weights. 
Additionally dithiothreitol (DTT) or β-mercaptoethanol is used in this process to 
further denaturate the protein sample. Due to their thiol group (-SH), 
β-mercaptoethanol and DTT are able to reduce existing disulfide linkages. Proteins 
were separated on discontinuous polyacrylamide (PAA) gels. Gel compositions are 
depicted below (Table 10). For the analysis, 10 µg of total protein was applied to 
SDS-PAGE with subsequent western blotting. The protein concentrations were 
previously determined as described above (BCA assay). All samples were mixed 
with SDS sample buffer and heated to 95°C for at least 15 min. The commercially 
available Spectra™ Multicolor Broad Range protein ladder (Thermo Scientific, 
Waltham; MA USA) was used as molecular standard. Electrophoresis was 
performed using SDS-electrode buffer at 200V constant for 45 min.
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Table 10: gel composition for SDS-PAGE 
 collection gel 4,5 % separation gel 12,5 % 
gel buffer I pH 8,8  1250 µL 
gel buffer II pH 6,8 1300 µL  
acrylamid 30 % 835 µL 2085 µL 
Ammonium persulfate 10 % 30 µL 30 µL 
TEMED 15 µL 15 µL 
H2O bidest 2895 µL 1645 µL 
  volume 5075 µL   5025 µL 
 gel buffer I gel buffer II 
 1,5 M Tris 500 mM Tris 
 0,4 % SDS (w/v) 0,4 % SDS (w/v) 
 ad 250 mL H2O bidest ad 250 mL H2O bidest 
  SDS-sample buffer SDS-electrode buffer 
 125 mM Tris-HCl 25 mM  Tris 
 10 % SDS 200 mM glycin 
 5 % β-mercaptoethanol 10 % SDS 
 20 % glycerol 20 % methanol 
 0.1 % brominephenol blue ad 5 L H2O bidest 
 ad 10 mL H2O bidest 
Western Blot 
The separated proteins were transferred to a polyvinylidene difluoride (PVDF) 
membrane. Transfer was conducted with 25V for 15 min on a Trans-Blot® Turbo™ 
Transfer System (BioRad, Hercules; CA USA) with the appropriate buffer system as 
supplied by the manufacturer. After the transfer, the membrane was blocked with 
5 % milk in TBS-T. Primary antibody (Table 1: HO-1) was also diluted in blocking 
reagent to prevent unspecific binding. The incubation with the primary antibody 
was conducted over night at 4°C under continuous shaking. Next day, the 
membranes were washed thrice to discard remaining unbound primary antibodies 
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and the HRP-conjugated anti-mouse IgG (Table 2) diluted in TBS-T was applied to 
the blot. Antibodies were detected using the chemiluminescence reagent 
Immobilon™ Western (Millipore, Darmstadt; Germany) as recommended by the 
manufacturer. Luminescence signals were visualized on photo-sensitive 
Hyperfilm™ ECL (GE Healthcare Life Science, Chalfont St. Giles; United Kingdom) in 
a dark room under exclusion of light. For normalization of HO-1 protein content, 
the same membrane was used to detect the protein amount of a reference as 
loading control. Therefore, antibody-complexes were removed with Roti®-Free 
Stripping Buffer (Carl Roth, Karlsruhe; Germany) for 15 min at 60°C. Afterwards, 
the membrane was blocked once more and subsequent antibody incubation could 
take place. 
Luminometer assay 
Luminometer assays were performed using the GloMax® 96 microplate 
luminometer (Promega, Madison, WI USA). Cells or tissues were homogenized in 
passive lysis buffer PLB (Promega, Madison, WI USA). For the detection of 
luciferase activity, the commercially available LAR I from Promega (Madison, WI 
USA) was used. Therefore, 50 µL of sample was prepared in a white 96-well plate. 
LAR I was added by the luminometer directly before (0.4 ms) luminescence 
measurement. Integration time for all measurements was set to 10 seconds. 
Enzyme-linked immunosorbent assay (ELISA) 
The concentrations of IL-1β and IL-6 in the synoviocyte (K4IM) culture 
supernatants were determined by ELISA. The assays were performed according to 
the manufacturer's instructions (Life Technologies, Carlsbad; CA USA). 
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Luminex LiquiChip assay 
The Luminex LiquiChip System (Qiagen, Hilden, Germany), which is based on 
Luminex's xMAP® technology, combines flow cytometry, fluorescent 
microspheres, and traditional biochemistry into a flexible, multi-analyte profiling 
technology. It differs from conventional ELISA in a significant way— the capture 
antibody is attached to a bead whereas the ELISA capture antibody is immobilized 
to the microplate well.  
 
Fig. 8 Illustration of the multiplex concept used by Luminex technique. 
(http://www.panomics.com/products/luninex-assays/technical-overview/how-it-works) 
The use of the suspension bead-based technology enables the multiplexing 
capabilities of the Luminex® assays. The technology uses 5.6 micron polystyrene 
or magnetic microspheres, which are internally dyed with red and infrared 
fluorophores of differing intensities. Each bead is given a unique bead region, 
allowing differentiation of one bead from another (Fig. 8). All together beads 
covalently bound to different antibodies can be mixed in the same assay and 
therefore simultaneously be measured in 96-well microplate format. Beads can be 
analyzed in appropriate detection systems by dual lasers for classification and 
quantification of each analyte. Cytokines were measured using invitrogen murine 
cytokine 4-plex kit (Life Technologies, Carlsbad; CA USA) for BMDM supernatants. 
Liver homogenates were analyzed with the murine cytokine 23-plex kit 
(Invitrogen, Carlsbad; CA USA). Calibration curves from recombinant cytokine 
standards were prepared with threefold dilution steps in the same matrix as the 
samples. Standards and samples were measured in duplicates, and blank values 
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were subtracted from all readings. All assays were carried out directly in a 96-well 
filtration plate (Millipore, Darmstadt; Germany) at room temperature and 
protected from light. Briefly, wells were pre-wet with 100 μL PBS containing 1 % 
BSA, then beads together with a standard, sample or blank were added in a final 
volume of 100 μL, and incubated at room temperature for 30 min with continuous 
shaking. Beads were washed three times with 100 μL PBS containing 1 % BSA and 
0.05 % Tween 20. A cocktail of biotinylated antibodies (50 μL/well) was added to 
the beads for further 30 min incubation with continuous shaking. After beads were 
washed three times, streptavidin-PE was added for 10 min. Beads were again 
washed three times and resuspended in 125 μL of PBS containing 1 % BSA and 
0.05 % Tween 20. The fluorescence measurement of the beads was conducted with 
the Qiagen LiquiChip 200 workstation (Hilden, Germany). Bio-Plex Manager 
software (Bio-Rad, Hercules; CA USA) with five-parametric-curve fitting was used 
for data analysis. 
Determination of reactive oxygen species (ROS) 
H2DCF-DA reagent 
For the general detection of total reactive oxygen species (ROS) formation the 
fluorogenic probe H2DCF-DA was used. Chemically reduced and acetylated forms 
of 2′,7′-di-chlorofluorescein (DCF) are nonfluorescent until the acetate groups are 
removed by intracellular esterases and oxidation occurs within the cell. 
To load the cells with this dye, the normal growth medium was removed, the cells 
were washed with pre-warmed PBS and supplied with Opti-MEM® (life 
technologies, Carlsbad; CA USA) medium including 10 µM H2DCF-DA. The 1 mM 
stock solution was always prepared shortly before the experiment was performed. 
Cells were incubated with the reagent for 45 minutes under physiological 
conditions in the dark. Further working steps were conducted among exclusion of 
light. After the cells were loaded with the dye, medium was replaced by normal 
growth medium and stimulation could take place. Signal intensities were 
measured and quantified with the infinite® M200 96-well fluorescence reader 
(Tecan, Crailsheim, Germany). 
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Lucigenin reagent 
Lucigenin is a di-acridinium compound, which emits light on reaction with 
superoxide. Initially, lucigenin gets reduced to a radical. The lucigenin radical can 
then react with either oxygen, producing superoxide, or with superoxide in an 
addition reaction. This leads to the decomposition of the lucigenin into two 
acridones, one of which is in an excited state, and decays to produce light. The 
main point of criticism using the lucigenin assay for superoxide measurement is 
the circumstance that lucigenin itself can react to produce superoxide. Therefore, it 
is important to include proper controls in the experimental setup to prevent 
misinterpretation of data. 
Commercial assays 
WST assay 
A 4-[3-(4-iIodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate (WST) assay was used to measure cell viability. Therefore, the HSE 
cells were stimulated as described before. After the stimulation, the media were 
supplemented with 10 µL/well (96- well plate) WST 2 h before 
spectrophotometric evaluation. Conversion of WST to formazan was measured at 
450 nm by microplate spectrophotometry. This reaction reflects the reductive 
capacity of the cells, thereby representing the viability. 
CytoTox Glo 
CytoTox-Glo™ cytotoxicity assay (Promega, Madison, WI, USA) was used to 
measure cytotoxicity. Cells were seeded in 96-well plates and treated as before (cf. 
WST assay). The kit was used according to the manufacturer’s recommendation. 
Luminescence was measured in a 96-well plate reader (GloMax®™- 96 microplate 
luminometer; Promega, Madison, WI, USA). 
Caspase 3/7 Glo 
For measurements of caspase 3 and 7 activity, the Caspase-Glo®™ 3/7 assay 
(Promega, Madison, WI, USA) was carried out according to the manufacturer's 
MATERIALS & METHODS 
61 
instructions. Cells were treated as described for the WST and CytoTox Glo™ assay. 
This assay is based on the cleavage of the DEVD sequence of a luminogenic 
substrate by caspase 3 and 7, which results in a luminescent signal, which was also 
detected in the GloMax®™-96 microplate luminometer. 
Histology/Immunohistochemistry 
Sample preparation and fixation 
Fresh isolated tissue (see above) was fixed in 4 % neutral buffered formalin for 
approx. 24h depending on tissue dimension (diffusion speed of formalin 
~ 1 mm/h). After fixation, the samples were prepared for paraffin embedding 
through an increasing ethanol sequence: 
• ethanol   50 %    2 hours 
• ethanol   70 %  72 hours 
• ethanol   80 %     3 hours 
• ethanol   90 %  24 hours 
• ethanol   96 %     3 hours 
• ethanol 100 %  24 hours 
Paraffin embedding 
After fixation and ethanol pre-treatment, the specimen were rinsed in Histosolve I 
(Thermo Scientific, Waltham; MA USA) for one hour and subsequently in 
Histosolve II for another hour. Paraffin coating was conducted in four steps: 
• Paraplast I  18 hours 
• Paraplast II  24 hours 
• Paraplast III   72 hours 
• Paraffin embedding 
For histological and immunohistochemical processing of the embedded samples, 
the tissue was subsequently sliced to 6 µm thick sections using a sledge 
microtome. 
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Hematoxylin & Eosin staining 
Hematoxylin & Eosin (HE) staining was done according to standard operation 
procedures (SOP) for this method. The sections were deparaffinized and 
rehydrated, stained and subsequently embedded and covered: 
Deparaffinizing: 
• 2 x 10 min xylol 
• 5 min isopropanol 
• 5 min ethanol 100 % 
• 5 min ethanol 96 % 
• 5 min ethanol 80 % 
• 5 min ethanol 70 % 
• rinsed in H2O bidest 
HE staining: 
• 10 min in hematoxylin 
• 10 min in tap H2O until color changes to blue 
• rinsed in H2O bidest 
• 5 min in eosin 
• rinsed in H2O bidest 
Embedding: 
• shortly doused in ethanol 70 % 
• 1 min in ethanol 80 % 
• 2 min in ethanol 90 % 
• 2 min in ethanol 96 % 
• 5 min in ethanol 100 % 
• 2 x 10 min in xylol 
• embedding in Kaiser's glycerol gelatin 
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Congo red staining 
Amyloid deposition in the brains of APP/Psen1 mice was investigated with congo 
red staining. This staining is also used in medicine for the detection of amyloid 
deposition in human brain tissue post mortem. Congo red was obtained from Sigma 
Aldrich as ready-to-use staining kit (HT60-1KT). The procedure was performed as 
recommended by the manufacturer. After deparaffinizing and rehydration, 
sections were stained with hematoxylin to visualize the nuclei. Afterwards, the 
working sodium chloride solution was applied for 20 min at RT and the working 
congo red solution was added for 1h at RT. After staining, the sections were rapidly 
dehydrated in absolute ethanol and rinsed in xylol. Sections were mounted in 
Depex embedding medium. 
Immunohistochemical staining 
The localization and expression pattern of specific proteins was analyzed by 
immunohistochemical staining. Therefore, the sections were deparaffinized as 
described above. Afterwards, tissue-specific peroxidases were blocked by H2O2 
treatment for 15 min. All washing steps were done in TRIS-HCl-Buffer. Antigen 
retrieval was conducted by heating the sections 3 x 7 min in a microwave at 600 W 
in 10 mM citric acid buffer pH 6.0. Before antibody incubation, the slides were 
blocked with the secondary antibody’s host serum to prevent unspecific binding. 
Used primary antibodies including concentrations or dilution factors are listed in 
Table 1. Primary antibodies (see Table 1) were diluted in TRIS-HCl-Buffer 
supplemented with 1.5 % BSA and were applied overnight at 4°C. Next day, the 
slides were treated with biotin conjugated secondary antibodies (see Table 2) for 
1 h at room temperature. Signal amplification was carried out with HRP-
(horseradish peroxidase) conjugated streptavidin treatment for 10 min at RT. 
Visualization was performed with 3-Amino-9-ethylcarbazole (AEC) staining kit 
from life technologies (Carlsbad; CA USA) as recommended in the manual. Slides 
were counterstained with hematoxylin (see section about HE staining) afterwards 
to additionally visualize the nuclei of cells. Samples were ready for microscopy 
after slides were embedded and dried overnight in Kaiser’s glycerol. 
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Microscopy and data analysis 
All microscopic work was conducted with the BZ-9000 system from Keyence 
(Osaka, Japan) using the ability of this microscope to make serial pictures of a pre-
defined region of interest (scanning). These pictures were combined to a complete 
picture of this region in high resolution afterwards. This feature is called “merge-
function”. Detailed description of this function can be found in the user manual of 
the BZ-9000 device. Staining intensities were analyzed and quantified with the 
built-in software module “color extraction mode” which is comparable to intensity 
analysis using ImageJ. 
Statistics 
All data represent mean + SEM. Analyzes of parametric data were carried out with 
Student’s t-test or by One-Way ANOVA, followed by appropriate corrections or 
post-hoc tests as indicated in the results. If necessary, BoxCox transformation was 
performed to achieve homoscedasticity. Normal distribution was validated with 
the Shapiro-Wilk test. Non-parametric data were analyzed with the Mann-Whitney 
test or the Kruskal-Wallis test followed by Dunn’s post-hoc test. Learning curves 
were analyzed by calculating the area under the curve (AUC) and following 
parametric statistics. All statistical analyzes were carried out with 
GraphPad Prism 5 (GraphPad, La Jolla; CA USA), JMP 9.03 (SAS Institute, Cary; NC 
USA) and SPSS software (IBM, Armonk, New York; NY USA). 
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RESULTS 
The role of Nrf2 in monocytes/macrophages 
In vitro approaches were used to investigate the involvement of Nrf2 in 
inflammatory processes using primary bone-marrow derived macrophages 
(BMDMs), the murine macrophage cell line RAW 264.7 and human THP-1 cells as a 
model of monocytes. 
Inflammatory stimuli induce Nrf2/ARE activity 
Our group already demonstrated that the Nrf2/ARE signaling cascade is involved 
in inflammatory processes as Nrf2 activity was time-dependently induced in the 
in vivo AIA (antibody induced arthritis) mouse model of Rheumatoid Arthritis 25. 
Based on these results an in vitro study with phagocytic cell lines and primary 
macrophages was supposed to reveal new insights into the interaction between 
inflammatory mediators and Nrf2 signaling. For that purpose THP-1 and 
RAW264.7 cells stably transfected with the pGL4.17-ARE vector or primary murine 
BMDM from ARE-luc mice were stimulated with various pro- and 
anti-inflammatory cytokines for different incubation times. First, these cells were 
stimulated with TNF-α as an exemplary pro-inflammatory cytokine. Nrf2 activity 
was analyzed by ARE-luciferase reporter gene assay. Signal intensities were 
normalized to protein concentration of the samples and shown in relation to the 
untreated control group. 
 
Fig. 9 TNF-α stimulation induced Nrf2 activity in phagocytic cells. THP-1 pGL4.17-ARE cells (Α), RAW264.7 
pGL4.17-ARE cells (B) and primary ARE-luc BMDM (C) were stimulated with 10 ng/mL TNF-α for 3h, 6h, 12h and 
24h. After treatment the cells were lysed in PLB and forwarded to luciferase reporter gene assays. Raw luminescence 
signals were normalized to total protein content and all groups were related to untreated control cells. In all cell types 
TNF-α stimulation resulted in a significant induction of Nrf2 after about 6h of stimulation. Data represent 
mean + SEM; n = 8; * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control. One-Way ANOVA with Bonferroni post 
hoc test (GraphPad Prism 5, La Jolla, USA) 
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TNF-α stimulation significantly induced Nrf2 activity in all investigated cell types. 
In THP-1 cells TNF-α stimulation induced Nrf2 activity to a significant level after 
6h. The maximum of Nrf2 activation (Fig. 9A: 2-fold of control) was found after 12h 
TNF-α treatment, thereafter Nrf2 activity decreased to 1.5-fold after 24h. Similar 
time-dependency was observed in RAW264.7 cells and primary murine BMDM. 
Nrf2 was significantly induced after 3h in RAW264.7 and after 12h in BMDM. 
Again, the maximal Nrf2 activation was found after 12h TNF-α treatment with 
2.12-fold in RAW264.7 (Fig. 9B) and 1.74-fold in BMDM (Fig. 9C). In both cell types 
Nrf2 activity decreased with further treatment as already seen in THP-1 cells. 
These proof of principle trials led to additional studies using the pro-inflammatory 
cytokines interleukin-1beta (IL-1β), interleukin-6 (IL-6) and interferon gamma 
(IFNγ) as stimulants for RAW264.7 pGL4.17-ARE cells . 
 
Fig. 10 Prominent pro-inflammatory cytokines induced Nrf2 in RAW264.7 cells. RAW264.7 pGL4.17-ARE 
cells were treated with 10 ng/mL each IL-1β (A), IL-6 (B) and IFNγ (C) for 3h, 6h, 12h and 24h. Untreated cells 
dealt as control. After treatment the cells were lysed in PLB and forwarded to luciferase reporter gene assays. 
Luminescence signals were normalized to total protein content and all groups were related to untreated control cells. 
All cytokines cause significant increase of Nrf2 activity. Data represent mean + SEM;  n = 8; * p < 0.05, ** p < 0.01 
and *** p < 0.001 vs. control. One-Way ANOVA with Bonferroni post hoc test (GraphPad Prism 5, La Jolla, USA) 
The stimulations of RAW264.7 cells with other pro-inflammatory cytokines 
confirmed the findings from before. All investigated pro-inflammatory cytokines 
were able to induce Nrf2 activity in RAW264.7 cells. IL-1β treatment showed a 
similar activation scheme like TNF as the signal maximum (1.64-fold) was reached 
after 12h stimulation and decreasing signal intensity after 24h (Fig. 10A). 
Stimulations with IL-6 and IFNγ revealed another kind of activation. Both 
cytokines caused a continuously increasing Nrf2 activity, with no decline after 24h 
as seen before. Signal maximum was reached after 24h for both cytokines with IL-6 
treatment resulting in a 2.16-fold induction of Nrf2 activity (Fig. 10B), whereas 
IFNγ showed up as the most potent Nrf2 inducer of the investigated cytokines with 
a 16.1-fold induction (Fig. 10C) compared to untreated control cells. 
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Cytokine production and secretion is a typical response of the immune system, 
when confronted with pathogens and other xenobiotics. Cells of the innate immune 
system express specific pattern recognition receptors (PRR) to recognize special 
pathogen-associated molecular patterns (PAMPs). PAMP interaction activates 
pro-inflammatory signaling cascades. In further analyzes, representative 
substances were used to investigate whether PAMPs also affect Nrf2 activation in 
RAW cells and thus play a role in the interplay between Nrf2 and inflammation. 
Lipopolysaccharide (LPS), recognized by Toll-like receptor 4 (TLR4), to represent 
gram-negative bacteria, peptidoglycan (PGN), recognized by peptidoglycan 
recognition proteins (PGRPs) and expressed in gram-positive bacteria and 
zymosan, a substance found on the surface of yeast and recognized by Toll-like 
receptor 2 (TLR2) were used to stimulate PRRs. 
 
Fig. 11 PRR signaling induced Nrf2 activity after PAMP stimulation of RAW264.7 cells. RAW264.7 
pGL4.17-ARE cells were treated 100 ng/mL LPS (A), 100 µg/mL zymosan (B) and 10 ng/mL PGN (C) for 3h, 6h, 
12h and 24h. Untreated cells were used as control. After treatment the cells were lysed in PLB and forwarded to 
luciferase reporter gene assays. Raw luminescence signals were normalized to total protein content and all groups are 
shown in relation to untreated control cells. Stimulation with PAMPs resulted in significantly increased Nrf2 activity. 
LPS and zymosan treatment furthermore exhibit similar activation patterns as seen before. Data represent 
mean + SEM; n = 8; *** p < 0.001 vs. control. One-Way ANOVA with Bonferroni post hoc test (GraphPad Prism 5, 
La Jolla, USA) 
Stimulation experiments with PAMPs further consolidated previous data. LPS and 
zymosan treatment resulted in similar activation patterns as observed after 
stimulation with pro-inflammatory cytokines. Maximum Nrf2 activity was 
detectable after 12h with a 6.14-fold induction after LPS (Fig. 11A) and a 4.32-fold 
induction after zymosan treatment (Fig. 11B). Nrf2 activity was slightly decreased 
24h after stimulation compared to the 12h stimulation. The stimulation with 
peptidoglycan revealed another activation pattern as there was no obvious time-
dependency found. Indeed, the maximal Nrf2 activity (Fig. 11C: 2.75-fold) was 
observed once more after 12h treatment, but after 3h, 6h and 24h it was mostly 
comparable to that. 
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Anti-inflammatory cytokines do not induce the Nrf2/ARE activity 
The aim of the following experiment was to find out if anti-inflammatory cytokines 
do also activate Nrf2. Therefore interleukin-4 (IL-4) and interleukin-10 (IL-10) 
were used as representative anti-inflammatory cytokines, which are secreted 
during the resolution of inflammation. The stimulation was performed using 
RAW264.7 pGL4.17-ARE cells. 
 
Fig. 12 Anti-inflammatory cytokines did not induce Nrf2 activity in RAW264.7 cells. RAW264.7 pGL4.17-ARE 
cells were stimulated with 10 ng/mL IL-4 (A) and 10 ng/mL IL-10 (B) for 3h, 6h, 12h and 24h. Untreated cells dealt 
as control. After treatment the cells were lysed in PLB and forwarded to luciferase reporter gene assays. 
Luminescence signals were normalized to total protein content and all groups were related to untreated control cells. 
Neither IL-4 nor IL-10 treatment resulted in significant Nrf2 induction. Data represent mean + SEM; n = 8; One-Way 
ANOVA with Bonferroni post hoc test (GraphPad Prism 5, La Jolla, USA) 
Both, IL-4 and IL-10 stimulation did not affect Nrf2 activity (Fig. 12). There was no 
significant induction observed during investigated time points, merely a minor 
trend after IL-4 treatment (Fig. 12A), which was statistically not significant. 
ROS, ERK and p38 MAPK are involved in the signaling cascade of Nrf2 
activation 
To get a more detailed view on underlying signaling of the observed effects, the 
study was further extended. Since TNF-α signaling is mediated by the TNF-α 
receptors (TNFR), which activate NADPH oxidases (NOX2) 54-56 and these in turn 
produce reactive oxygen species (ROS), ROS detecting assays were used to 
measure ROS production in TNF-α stimulated RAW264.7 cell. The H2DCF-DA 
reagent was used to generally detect total ROS production, while the lucigenin 
assay was conducted to get a detailed view on superoxide production. To 
distinguish whether NADPH oxidases are involved during ROS production, several 
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NOX inhibitors (DPI: diphenyl iodonium chloride; apocynin and gp91-ds-tat) were 
applied during TNF-α treatment. 
 
Fig. 13 TNF-α induced NOX-dependent ROS respectively superoxide. RAW264.7 cells were stimulated with 
10 ng/mL TNF-α with or without pre-treatment with NOX inhibitors. The H2DCF-DA (A) and lucigenin (B) assays 
were conducted as described in Materials and Methods. Both assays were analyzed in a 96-well microtiter plate 
reader, obtaining fluorescence from the H2DCF-DA and luminescence from the lucigenin assay. TNF-α stimulation 
resulted in increased ROS as well as superoxide production. The use of specific NOX inhibitors counteracted 
increased ROS appearance. Data represent mean + SEM; n = 6; ### p < 0.001 as indicated, *** p < 0.001 vs. control. 
One-Way ANOVA with Bonferroni post hoc test (GraphPad Prism 5, La Jolla, USA) 
RAW264.7 cells produced a significant amount of ROS (Fig. 13A: RLU 45538 vs. 
31295) respectively superoxide (Fig. 13B: RLU 45.23 vs. 29.12) in response to 
TNF-α stimulation compared to untreated control cells. Total ROS production as 
well as superoxide production was significantly decreased after application of 
specific NOX inhibitors in RAW264.7 cells. 
Considering that TNFRs activate several MAP kinases, additional inhibitor 
experiments were implemented to investigate its role in Nrf2 activation. Therefore, 
several antioxidants, NADPH oxidase and kinase inhibitors were applied during 
TNF-α treatment of RAW264.7 pGL4.17-ARE cells to investigate the involvement of 
targeted molecules on Nrf2 activity. DPI was applied to inhibit NOX activity and 
ROS production, glutathione-monoethyl esther (GME), N-acetyl-cysteine (NAC) and 
dithiotreitol (DTT) were used as ROS scavenging substances. MEK1/2 and ERK1/2 
kinase activity were inhibited by U0126 and PD98059, respectively. Inhibition of 
JNK activity was ensured by SP600125 pre-treatment. p38 MAP kinase and PI3K 
were inhibited by SB203580 and wortmannin, respectively. 
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Fig. 14 NOX, ERK and p38 MAPK activity are involved in TNF-α mediated Nrf2 activation. RAW264.7 
pGL4.17-ARE cells were either pre-treated with indicated substances/inhibitors and TNF-α afterwards or just treated 
with 10 ng/mL TNF-α for 12h. After treatment the cells were lysed in PLB and forwarded to luciferase reporter gene 
assays. Luminescence signals were normalized to total protein content and all groups were related to untreated 
control cells. ROS scavenging by antioxidants (GME, NAC or DTT) or NOX inhibition by DPI resulted in 
significantly reduced Nrf2 activity compared to TNF-α treatment alone. Furthermore, the inhibition of ERK (U0126 
& PD98059) and p38 (SB203580) kinases also lead to a significantly reduced Nrf2 activity. Data represent 
mean + SEM; n = 6; # p < 0.05 as indicated, * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. TNF-α. One-Way ANOVA 
with Bonferroni post hoc test (GraphPad Prism 5, La Jolla, USA) 
TNF-α mediated Nrf2 activity was decreased by specific NOX inhibition due to DPI 
treatment (Fig. 14A 2nd and 3rd columns: 1.66-fold TNF-α vs. 1.43-fold DPI) as well 
as ROS scavenging by GME, NAC and DTT (Fig. 14A 1.66-fold TNF-α vs. 1.32-fold 
GME, 1.47-fold NAC and 1.48-fold DTT). Moreover, ERK and p38 kinase inhibition 
also decreased TNF-α dependent Nrf2 activation (Fig. 14B). Inhibition of ERK 
kinase activation almost totally abolished TNF-α mediated Nrf2 induction (Fig. 14B 
1.68-fold TNF-α vs. 1.41-fold U0126 and 1.07-fold PD98059). A similar effect was 
observed by inhibition of p38 MAP kinase activity with SB203580 (Fig. 14B 2nd and 
6th column: 1.68-fold TNF-α vs. 1.19-fold SB203580). Specific inhibition of JNK and 
PI3K did not affect Nrf2 activation as shown in Fig. 14B. 
TNF-α mediated Nrf2 activity leads to increased expression of HO-1 and 
NQO1 
To evaluate the impact of the observed Nrf2 activation due to pro-inflammatory 
mediators, further analysis of established Nrf2 target genes was done. On that 
matter the expression of NADPH oxidoreductase1 (NQO1) and heme oxygenase-1 
(HO-1) was examined by qRT-PCR using RAW264.7 cells. HO-1 protein expression 
was further investigated by western blot. Both, NQO1 and HO-1 are important 
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enzymes, which carry out a crucial role in oxidative stress defense. Furthermore, 
HO-1 is known to act anti-inflammatory 57 due to its side-product carbon 
monoxide (CO), which is produced during heme transformation. CO is described to 
exert its anti-inflammatory property by inhibiting the pro-inflammatory 
transcription factor nuclear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) 58. 
 
Fig. 15 TNF-α mediated Nrf2 activation induced NQO1 and HO-1 expression. RAW264.7 cells were stimulated 
with 10 ng/mL TNF-α for various durations. After treatment RNA was isolated, cDNA was synthesized and gene 
expression of HO-1 (A) and NQO1 (B) was analyzed by qRT-PCR (n = 6). Expression levels were normalized to the 
expression of the two reference genes TBP and GAPDH, as they were established (GeNorm) as the most stable ones 
under these conditions. The transcription of both genes was induced due to TNF-α treatment in the same period of 
time as Nrf2 activation was observed in the previous experiments. Furthermore, RAW264.7 cells were stimulated for 
12h with 10 ng/mL TNF-α. Protein samples were obtained and western blot analysis was conducted for HO-1 protein 
content. Expression of HO-1 was normalized to β-actin expression (C). Band intensities were analyzed 
densitometrically and data were normalized to untreated control samples (D) n = 3. Data represent mean + SEM; 
* p < 0.05 and ** p < 0.01 vs. control. A and B: One-Way ANOVA with Bonferroni post hoc test; D: two-tailed 
Student’s t-test with Welch’s correction (GraphPad Prism 5, La Jolla, USA) 
The qRT-PCR experiments revealed that the transcription of the Nrf2 target genes 
NQO1 and HO-1 was significantly induced after TNF-α stimulation. Significant 
induction of HO-1 transcription was not observed until 6h TNF-α treatment and 
was increased up to 5.23-fold of control after 24h stimulation (Fig. 15A). The same 
trend was observed for NQO1 gene expression. Significant induction of NQO1 
expression was detected after 6h stimulation. Gene expression level further 
increased after 12h TNF-α stimulation up to 3.31-fold of control (Fig. 15B). HO-1 
protein amount was further analyzed by western blot technique. As depicted in 
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Fig. 15C and D, HO-1 was also induced on protein level after 12h TNF-α 
stimulation. The resulting western blot plot is depicted in Fig. 15C. Three protein 
samples of each, untreated control and TNF-α treated cells were used. HO-1 
protein content of TNF-α treated RAW264.7 cells was significantly increased (Fig. 
15D: 1.58-fold) compared to untreated control cells. 
LPS tolerance is Nrf2-dependent 
Macrophages, which are stimulated with pro-inflammatory mediators, develop a 
tolerance against further inflammatory stimuli. In detail, a prolonged stimulation 
with a pro-inflammatory stimuli leads to a reduced inflammatory response, if the 
cells are subsequently treated a second time. Literature gives evidence that the 
formation of this tolerance is an indirect indication for a polarization switch of 
macrophages from a pro-inflammatory M1 to an anti-inflammatory M2 phenotype 
39. The best-established model for this concept is the so-called LPS tolerance 
approach 59,60, in which cells are treated with LPS twice. RAW264.7 cells stably 
expressing shRNAs either directed against Nrf2 or Keap1 and primary murine 
BMDM from Nrf2-KO and Keap1ΔVaV-iCre-KO were used to examine the influence of 
Nrf2 on LPS tolerance formation. RAW264.7 cells were furthermore transduced 
with the SIN-lenti-NF-κB construct to visualize NF-κB activity by luminometer 
assays. Supernatants from BMDM were collected from cells, which were untreated, 
treated 24h with LPS and 24h pre-treated and subsequently stimulated once again 
with LPS for 4h. These supernatants were used for Luminex LiquiChip multiplex 
analyzes of TNF-α and IL-6 protein content. 
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Fig. 16 Nrf2 influences inflammation severity and LPS tolerance. RAW264.7 SIN-lenti-NF-κB cells, which 
stably express shRNAs either directed against Nrf2 or Keap1 were stimulated with LPS for 24h and NF-κB 
depending luminescence was measured in a luminometer. Cells expressing a shNonTarget construct were used as 
control cells (A). BMDM from Nrf2-KO and Keap1∆VaV-iCre-KO mice were stimulated with LPS for 24h. 
Supernatants were analyzed for TNF-α (B) and IL-6 (C) protein content by Luminex LiquiChip multiplex technique. 
BMDM were also used for LPS tolerance experiments and TNF-α (D) and IL-6 (E) concentration in supernatants 
were determined by Luminex assays. Data represent mean + SEM; n = 6; A,B and C: ### p < 0.001 as indicated, 
** p < 0.01 and *** p < 0.001 vs. control; D and E: ** p < 0.01 and *** p < 0.001 as indicated. Two-Way ANOVA 
with Bonferroni post hoc test (GraphPad Prism 5, La Jolla, USA). 
LPS treatment was able to induce NF-κB activation in all investigated genotypes, 
but Nrf2 knockdown resulted in a significant increase of NF-κB activation 
compared to LPS stimulated shNonTarget cells (Fig. 16A: 64.66-fold vs. 35.53-
fold). In contrast, silencing of Keap1 led to a significantly decreased NF-κB 
activation (Fig. 16A: 18.34-fold vs. 35.53-fold). Analyzes of secreted 
pro-inflammatory cytokines (TNF-α and IL-6) due to LPS treatment resemble the 
NF-κB results in BMDM. LPS significantly induced cytokine production in all 
examined genotypes. TNF-α secretion was significantly increased in Nrf2-KO 
BMDM compared to treated wild type cells (Fig. 16B: 381.05 pg/mL vs. 
220.30 pg/mL). Otherwise, TNF-α secretion was lower in Keap1ΔVaV-iCre-KO than in 
wild type BMDM after 24h LPS treatment (Fig. 16B: 117.23 pg/mL vs. 
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220.30 pg/mL). Regarding IL-6 secretion the Luminex assay revealed a similar 
result, secretion was lower in Keap1ΔVaV-iCre-KO than in wild type but there was no 
significant difference found between Nrf2-KO and wild type cells (Fig. 16C: 
129.65 pg/mL wild type vs. 117.73 pg/mL Nrf2-KO). However, deficiency for 
Keap1 again resulted in lower secretion levels compared to the wild type BMDM 
(Fig. 16C: 62.97 pg/mL Keap1ΔVaV-iCre-KO vs. 129.65 pg/mL wild type). Single LPS 
treatment of wild type cells for 4h significantly induced TNF-α (Fig. 16D: 
96.79 pg/mL LPS vs. 4.03 pg/mL control) as well as IL-6 secretion (Fig. 16E: 
32.23 pg/mL LPS vs. 0.00 pg/mL control). Compared to single treated BMDMs, 
cells, pre-treated with LPS for 24h, generate significantly lower inflammatory 
response in terms of TNF-α or IL-6 secretion. Cytokine concentrations in the 
supernatants were reduced to 44.22 pg/mL for TNF-α and 8.77 pg/mL for IL-6. 
This reduction of the inflammatory response due to LPS pre-treatment is a 
consequence of LPS tolerance. These data show differences in the inflammatory 
response due to LPS single-treatment in investigated cells. Nrf2-KO cells secreted 
significantly more TNF-α (Fig. 16D: 238.90 pg/mL Nrf2-KO vs. 96.79 pg/mL wild 
type) but not IL-6 (Fig. 16E: 41.86 pg/mL Nrf2-KO vs. 32.23 pg/mL wild type) 
compared to their wild type control after 4h LPS. The knockout of Keap1 led to 
reduced TNF-α level (31.72 pg/mL) and IL-6 was even not detectable. 
Furthermore, the knockout of Nrf2 resulted in an altered LPS tolerance. 
Pre-treatment with LPS did not empower the cells to develop a tolerance against 
LPS, whereby the inflammatory response (TNF-α and IL-6 secretion) was not 
reduced in these cells (Fig. 16D and E). 
The role of Nrf2 in an in vitro model of Rheumatoid Arthritis 
To get a closer look on Nrf2’s involvement during inflammation an in vitro project 
was realized. Since synovitis is a crucial and key symptom of rheumatoid arthritis, 
the human synoviocyte cell lines K4IM and HSE were used to further investigate 
the role of Nrf2 under arthritic conditions. This was simulated in vitro by 
stimulations with TNF-α, because beside IL-1β TNF-α is one of the main cytokines 
playing a role in the pathogenesis of rheumatoid arthritis. The cells were 
additionally co-stimulated with sulforaphane (SFN), which is the most potent and 
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best described Nrf2 activator. SFN is a plant content which originates from the 
crucifer family. According to its molecular properties it belongs to the class of 
isothiocyanates and due to its electrophilic character, it is able to activate Nrf2 
through separation from Keap1. 
SFN inhibits TNF-α mediated NF-κB and AP-1 activity 
To analyze the NF-κB and AP-1 activation in vitro, a dual luciferase reporter gene 
assay utilizing the cis-acting elements of NF-κB and AP-1 was established. The 
synoviocyte cell line K4IM was pre-treated for 30 min with increasing 
concentrations of SFN or solvent (0.25 % DMSO) as control and subsequently 
stimulated with 10 ng/mL TNF-α for 6h. 
 
Fig. 17 SFN inhibits TNF-α-induced activation of NF-κB and AP-1. Synoviocytes (K4IM) were pre-treated 
(30 min) with increasing concentrations of SFN or solvent and stimulated with 10 ng/mL TNF-α for 6 h. Cells were 
transfected with pGL3-NF-κB (A) or pGL3-AP-1 (B) and dual-luciferase assay followed after lysis in PLB. 
Treatment groups were normalized to the control group (=1). All experiments were performed with n = 8. Data 
represent mean + SEM. Statistical significance is marked as *** p < 0.001.; One-way ANOVA with Bonferroni 
Multiple Comparison post-test (GraphPad Prism 5; La Jolla, USA) 
Stimulation with TNF-α activated the NF-κB dependent luciferase gene expression 
7-fold compared to the control. Pre-incubation with 0.5 µM SFN nearly halved the 
TNF-α induced activation to 3-fold over control. Doubling the SFN concentration 
further halved the TNF-α induced activation to 1.5-fold and pre-incubation with 
2.5 µM SFN completely restrained the TNF-α induced activation (Fig. 17A). 
Nearly the same effect of SFN could be seen with the cis-acting element of AP-1. 
The TNF-α-induced 6-fold induction of AP-1 dependent luciferase gene expression 
was reduced to 3.5-fold by pre-incubation with 0.5 µM SFN. Incubation with 1 µM 
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SFN further reduced the activation to 2.5-fold. TNF-α-induced AP-1 activation was 
completely blocked by 2.5 µM SFN (Fig. 17B). 
SFN inhibits the production of pro-inflammatory cytokines in synoviocytes 
In addition to NF-κB and AP-1 activity, the effect of SFN on TNF-α induced IL-1β 
and IL-6 secretion was examined. Therefore, synoviocytes (K4IM) were stimulated 
with 10 ng/mL TNF-α for 24h in the presence of 0, 0.5, 1.0, and 2.5 μM SFN and the 
concentration of IL-1β and IL-6 in the supernatant was measured via ELISA. 
 
Fig. 18 SFN inhibits TNF-α-induced production of IL-1β and IL-6. Synoviocytes (K4IM) were pre-treated 
(30 min) with increasing concentrations of SFN and stimulated with 10 ng/mL TNF-α for 6h. ELISA for IL-1β (A) 
and IL-6 (B) was measured as described in methods. Data represent mean + SEM; n = 8. Statistical significances are 
marked as * p < 0.05 vs. control, # p < 0.05 vs. TNF-α treated only. One-way ANOVA with Bonferroni Multiple 
Comparison post-test (GraphPad Prism 5; La Jolla, USA) 
SFN inhibited the TNF-α-induced release of IL-1β and IL-6 in a concentration-
dependent manner and this effect was already significant at the lowest tested 
concentration of 0.5 µM (Fig. 18A: 0.64 ng/mL TNF-α vs. 0.51 ng/mL 0.5 µM SFN). 
Both, IL-1β and IL-6 secretion was totally abolished, when the cells were 
co-stimulated with 2.5 µM SFN. 
SFN induces apoptosis in TNF-α stimulated synoviocytes 
Since enhanced proliferation of synoviocytes and thereby pannus formation is a 
hallmark of rheumatoid arthritis, a WST assay was used to examine whether SFN is 
able to inhibit this process by reducing cell viability. Cytotox-Glo and Caspase-Glo 
assays (Promega, Madison; WI USA) were performed to study the molecular 
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mechanism responsible for reduced viability and to analyze the effects of SFN on 
cell toxicity and apoptosis. For that purpose, HSE wild type cells were either left 
untreated or were pre-treated (3h) with 10 ng/mL TNF-α before being stimulated 
for 6h with 6.25 µM SFN. After stimulation the appropriate assays were performed. 
 
Fig. 19 SFN induces apoptosis in TNF-α pre-treated “transformed” synoviocytes. HSE wild type cells were 
either pre-treated (3h) with 10 ng/mL TNF-α and then stimulated for further 6h with 6.25 µM SFN or only stimulated 
for 6h with 6.25 µM SFN without TNF-α pre-treatment and WST (A), CytoTox-Glo™ (B) and Caspase-Glo® 3/7 
(C) assays were performed as recommended by the manufacturers. Data represent mean + SEM; n = 8. Statistical 
significances are indicated as * p < 0.05, ** p < 0.01, *** p < 0.001. One-way ANOVA with Bonferroni Multiple 
Comparison post-test (GraphPad Prism 5; La Jolla, USA). 
The results demonstrate that neither TNF-α nor SFN treatment alone had any 
cytotoxic effects compared to untreated control cells (Fig. 19B, 2nd and 4th column). 
In contrast, the treatment with TNF-α or SFN alone led to increased cell viability 
(Fig. 19A, 2nd and 4th column). Indeed, 6.25 µM SFN had a cytotoxic effect on TNF-α 
pre-treated but not on untreated cells (Fig. 19B, 3rd column). Thus, cell viability of 
co-treated cells was also decreased compared to single treated cells (Fig. 19A, 3rd 
column). The caspase enzyme activity assay confirmed these findings. These 
results demonstrate that there were no effects due to single-administration of 
TNF-α or SFN. However, a significant increase of caspase-3/7 activity was found 
after 6.25 µM SFN stimulation of TNF-α pre-treated cells (Fig. 19C, 3rd column). 
Nrf2/ARE-activity is crucial for the differential effects of the treatments 
In order to investigate the effects of TNF-α pre-treatment and SFN stimulation on 
Nrf2/ARE activity, a dual luciferase reporter gene assay with the ARE sequence of 
the rat NQO1 gene (pGL3-ARE) was carried out. Another aim was to examine 
whether Nrf2/ARE activation has an effect on growth and proliferation processes 
independent of the effects of SFN application. Therefore it was investigated to 
which extent the Nrf2/ARE activity is responsible for the observed effects on co-
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treated cells. HSE cells were transduced with the pLKO.1 vector containing a 
shRNA targeting Keap1 (the inhibitor of Nrf2), to provoke an increased Nrf2 
expression and activation, and performed a real-time analysis of cell proliferation., 
For that purpose the cells were treated with 10 ng/mL TNF-α 24h after seeding 
and were observed for further 24h by the RTCA device. The Cell Index was 
determined at three time points (TP) and the slope of the curve was calculated for 
three characteristic phases of proliferation. 
 
Fig. 20 Nrf2 activation leads to decreased proliferation of TNF-α pre-treated synoviocytes. HSE cells were 
co-transfected with pGL3-ARE/phRL-TK and either pre-treated (3h) with 10 ng/mL TNF-α and then stimulated for 
further 6h with 6.25 µM SFN or only stimulated for 6h with 6.25 µM SFN without TNF α pre-treatment. Afterwards 
dual luciferase reporter gene (DLR) assay was carried out (A - C). A real-time cell analysis (RTCA) experiment was 
performed with HSE cells stably transduced with either a shRNA targeting Keap1 mRNA or a shNonTarget control 
construct. 24h after seeding, the cells were treated with 10 ng/mL TNF-α and were observed for further 24h by the 
RTCA device (D). The Cell Index was determined at three time points (TP) (E) and the slope of the curve was 
calculated for three characteristic phases of proliferation (F). Data represent mean + SD; n = 8. Statistical 
significances are indicated as $ p < 0.05, $$ p < 0.01, $$$ p < 0.001 vs. control; ### p < 0.001 vs. all other groups; * 
p < 0.05, ** p < 0.01, *** p < 0.001 as indicated. (DLR: One-way ANOVA with Bonferroni Multiple Comparison 
post-test; RTCA analysis: Two-way ANOVA with Bonferroni post-tests, GraphPad Prism 5; La Jolla, USA). 
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The experiments showed that SFN induces Nrf2/ARE activity (Fig. 20A, 
4th column), in contrast to TNF-α, which caused no difference in ARE-driven 
luminescence compared to untreated cells (Fig. 20A, 2nd column). Co-stimulation of 
TNF-α pre-treated synoviocytes seemed to further increase the SFN mediated 
Nrf2/ARE activation (Fig. 20A, 3rd column), but analysis of the raw luminescence 
signals of the ARE-regulated firefly luciferase (pGL3-ARE) and the internal control 
renilla luciferase (phRL-TK) revealed a TNF-α dependent decrease in luminescence 
intensities in co-stimulated cells (Fig. 20B and D, 3rd column). There is evidence 
that the supposed increased ratio of co-stimulated cells is based on a decreased 
renilla mediated luminescence signal, resulting from a decreased amount of vital 
cells. 
TNF-α stimulation initially showed no difference in proliferation between the 
experimental groups (Fig. 20D, Phase 1). Comparing the untreated shKeap1 cell 
line with the untreated shNonTarget cells over the whole time, only a minor 
difference regarding the cell index (CI) was found. TNF-α treatment of 
shNonTarget cells resulted in increased proliferation compared to the untreated 
shNonTarget cells (Fig. 20D, Phase 3), as indicated by a higher cell index (Fig. 20E, 
TP 3 1st and 2nd column) and an increased proliferation rate (Fig. 20F, TP 3 1st and 
2nd column) after 24h stimulation time. The same TNF-α treatment showed the 
opposite effect in shKeap1 cells (Fig. 20D, Phase2). These cells exhibited a clearly 
decreased cell index (Fig. 20E, TP 3 1st column) and showed a lower proliferation 
rate already after 10h of stimulation with no recovery from this state during the 
entire experiment. 
The role of Nrf2 in the pathogenesis of sclerosing cholangitis 
A common dysfunction of liver homeostasis is found in the pathology of primary 
sclerosing cholangitis (PSC). This disease is mainly characterized by severe 
obstruction of the bile duct due to unrestrained proliferation of cholangiocytes, 
which comes along with bilirubinostasis, portal hypertension, inflammation and 
hepatomegaly. PSC can furthermore lead to cirrhosis and cancer. The following 
project was initiated to investigate the role of Nrf2 during the pathogenesis of PSC. 
Therefore, the well-established PSC mouse model of DDC feeding was used. 
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Bilirubinostasis, proliferation of cholangiocytes and infiltration of immune 
cells is increased in Nrf2-KO livers 
Sclerosing cholangitis was induced by DDC feeding as described in 
Materials & Methods. After treatment, mice were sacrificed and their bodyweight 
and the weight of their livers were measured to examine hepatomegaly. 
Afterwards, livers were prepared for hematoxylin & eosin (H&E) staining on the 
one hand and fresh snap-frozen specimen were taken for protein and RNA analysis 
on the other hand.  
 
Fig. 21 Nrf2-KO mice exhibit a more severe bilirubinostasis with enhanced proliferation of synoviocytes and 
immune cell infiltration. Wild type and Nrf2-KO mice were fed with chow containing 0.1 % DDC for 4 weeks to 
induce a sclerosing cholangitis. Control animals were fed with standard chow. After 4 weeks DDC treatment, all 
animals were sacrificed and liver tissue was obtained for analysis. Hematoxylin & eosin staining was conducted (A) 
for a general evaluation of liver morphology. Mice and livers were weighted to determine the relative liver weight 
(B). DDC feeding induced a cholangitis in both wild type and Nrf2-KO mice, but with more severe consequences in 
Nrf2-KO mice. Nrf2-KO mice exhibit increased bilirubinostasis, proliferation of cholangiocytes, immune cell 
infiltration and necrosis compared to treated wild type littermates. Data represent mean + SEM; n = 6; *** p < 0.001 
as indicated; One-way ANOVA with Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, 
USA). 
H&E staining revealed that DDC feeding induced the typical characteristics of a 
cholangitis in both wild type and Nrf2-KO mice. DDC feeding led to more severe 
bilirubinostasis (Fig. 21A; black arrows), increased proliferation of cholangiocytes 
(Fig. 21A; yellow arrows) and increased immune cell infiltration (Fig. 21A; white 
arrows) in Nrf2-KO mice compared to treated wild type mice. Furthermore, 
necrotic areas were observed more often and more severe in Nrf2-KO livers (Fig. 
21A; asterisk). Liver weights also differed between investigated genotypes even 
under control conditions. Nrf2-KO mice had a significantly reduced liver weight 
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compared to wild type animals (Fig. 21B; 1st and 2nd column). Under DDC 
treatment liver weight increases significantly in wild type and Nrf2-KO mice (Fig. 
21B; 3rd and 4th column) compared to control animals. Significant differences could 
be found between wild types and Nrf2-KO after DDC feeding, showing that Nrf2-KO 
mice have significantly lower liver weights than treated wild type littermates. 
Nrf2 target genes are lower and markers for fibrosis and inflammation are 
higher expressed in Nrf2-KO livers 
qRT-PCR experiments were conducted to see whether Nrf2 target genes are 
induced due to DDC feeding in the liver. Furthermore, markers for inflammation, 
cholangiocytes and fibrosis were measured. 
 
Fig. 22 Nrf2 targets are lower and markers for inflammation, cholangiocytes and fibrosis are higher expressed 
due to Nrf2 deficiency. Animals were treated with DDC as described above and untreated mice dealt as controls. 
After 4 weeks of DDC feeding, mice were sacrificed and RNA was isolated from snap-frozen liver tissue. qRT-PCR 
experiments were conducted for Nrf2 target genes (A – C), inflammatory cytokines (D – F), cholangiocytes (G) and 
fibrosis (H). Expression raw data from targets were normalized to the expression data from GAPDH and TBP. Data 
represent mean + SEM; n = 6; * p < 0.05, ** p < 0.01 and *** p < 0.001 as indicated; One-way ANOVA with 
Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, USA). 
The Nrf2 targets genes HO-1 (Fig. 22A), NQO1 (Fig. 22B) and γGCS (Fig. 22C) are 
significantly induced by DDC feeding in the liver of wild type animals. This 
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induction was reduced in Nrf2-KO mice. Furthermore, the mRNA expression of the 
pro-inflammatory cytokines TNF-α (Fig. 22D) and IL-1β (Fig. 22E) was 
significantly increased in Nrf2-KO but not in wild type livers. IL-6 mRNA 
expression (Fig. 22F) was not affected due to DDC treatment. CK19 (Fig. 22G) as a 
marker for cholangiocytes and Coll1a (Fig. 22H) as a marker for fibrosis were also 
elevated in both genotypes after DDC diet, but with significant differences between 
wild types and Nrf2-KOs. DDC feeding resulted in significantly greater expression 
levels of both markers in Nrf2-KO livers compared to treated wild types. 
HO-1 is expressed due to DDC in wild type but not in Nrf2-KO livers 
Since HO-1 is one of the most important target genes of Nrf2, not only due to its 
antioxidant but also because of its anti-inflammatory properties, western blot 
analysis for this protein in mouse livers were conducted. 
 
Fig. 23 HO-1 is induced in livers from wild type but not Nrf2-KO mice by DDC feeding. Mice were treated as 
described in methods. After 4 weeks of DDC feeding, animals were sacrificed and protein samples were obtained 
from snap-frozen tissue. Antibodies against HO-1 and GAPDH were used in western blot analysis to quantify the 
amount of HO-1 protein in examined samples. Densitometric analysis of western blot experiments are depicted in (A) 
and corresponding western blot plots are shown in (B). Data represent mean + SEM; n = 4; ** p < 0.01 and 
*** p < 0.001 as indicated; One-way ANOVA with Bonferroni’s multiple comparison post hoc test (GraphPad Prism 
5, La Jolla, USA). 
DDC feeding resulted in increased HO-1 protein expression with significant 
differences between genotypes regarding the extent of HO-1 induction. Livers of 
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wild type animals showed a HO-1 induction of up to 13.99-fold over control and 
Nrf2-KO mice a significant lower induction of 5.92-fold over control (Fig. 23A). The 
corresponding western blot plots are depicted in Fig. 23B. 
Inflammation is slightly induced by 4 weeks DDC feeding 
The inflammatory response in terms of mediator release after DDC treatment was 
analyzed by Luminex LiquiChip multiplex assays for cytokines and chemokines 
expressed by liver tissue. 
 
Fig. 24 Inflammation was just slightly induced after 4 weeks DDC without differences between wild type and 
Nrf2-KO mice. DDC treatment was conducted as described in the methods section. Snap-frozen tissue was prepared 
for Luminex LiquiChip assays as described by the manufacturer. Protein concentration of pro-inflammatory 
cytokines (A – C), anti-inflammatory cytokines (D – F), chemokines (G – I), G-CSF (J) and GM-CSF (K) were 
measured. Data represent mean + SEM; n = 5; ** p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control from same 
genotype; One-way ANOVA with Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, 
USA). 
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DDC feeding for 4 weeks slightly increased the secretion of inflammatory markers 
in the livers of the investigated animals. TNF-α secretion was neither induced in 
wild type nor in Nrf2-KO livers (Fig. 24A) but rather significantly reduced in wild 
types from 684.08 to 368.53 pg/mL after DDC treatment. IFN-γ protein 
concentration was negligibly induced in Nrf2-KO mice but not in wild type animals 
after DDC treatment (Fig. 24B: 28.76 vs. 13.68 pg/mL in Nrf2-KOs and 20.49 vs. 
17.66 pg/mL in wild types). IL-1β secretion seemed to show a trend to be 
increased in DDC-treated Nrf2-KO animals without reaching statistical significance, 
as shown in Fig. 24C. Analysis of anti-inflammatory cytokines showed a slightly 
increase in IL-5 (Fig. 24D) and IL-10 (Fig. 24F) in Nrf2-KO mice but not in wild 
type animals. Secretion levels of IL-6 were not affected (Fig. 24E). Secretion of 
CCL2 (Fig. 24H: 41.13 to 127.08 pg/mL in wild types, 36.01 to 119.93 pg/mL in 
Nrf2-KOs) was significantly induced after DDC feeding, but without any genotype 
specific differences. CCL4 was just elevated to a significant extent in Nrf2-KO (Fig. 
24I: 12.72 to 22.29 pg/mL). Analysis of CXCL1 secretion showed no changes due to 
DDC diet (Fig. 24G). Additionally, the secretion of G-CSF and GM-CSF was 
investigated, since these factors give suitable indications about granulocyte 
production and thus inflammatory status. G-CSF concentration was increased in 
both genotypes after DDC treatment (Fig. 24J: 0.65 to 10.20 pg/mL in wild types, 
0.61 to 13.20 pg/mL in Nrf2-KOs). GM-CSF secretion was also slightly induced in 
Nrf2-KO livers (Fig. 24K: 50.49 to 90.55 pg/mL in Nrf2-KOs). 
The role of Nrf2 in the pathogenesis of Alzheimer’s disease 
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases 
associated with onward aging. Beside aggregation of miss-folded amyloid-beta 
(Aβ) peptides causing oxidative stress, it is characterized by severe astrogliosis 
and microglia infiltration into affected brain regions, summarized as 
neuroinflammation. Consequences are a massive degeneration of neuronal tissue 
going hand in hand with severe cognitive impairments. Counteracting 
neuroinflammation and ongoing neurodegeneration would thus be a desirable 
approach. Taking this into account, the induction of Nrf2 during AD pathogenesis 
might be a working solution. For this reason the APP/Psen1 mouse model was 
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chosen to investigate possible benefits of methysticin-mediated Nrf2 activation. 
Methysticin belongs to the kavalactones, a class of molecules, which originate from 
the kava kava plant (lat.: Piper methysticum). These substances exhibit 
electrophilic properties, which empower them to activate Nrf2. Our work group 
already demonstrated in vitro that kavalactones are able to protect neuronal cells 
against Aβ-derived cytotoxicity and cell death due to Nrf2 activity 61. 
Methysticin induces Nrf2/ARE in the hippocampus and cortex 
A first experiment should proof if orally administered methysticin is able to 
activate Nrf2 in certain brain regions. For this purpose 6 mg/mL methysticin was 
applied to the ARE-luc mice by gavage at three consecutive days. After the 
treatment the brains were harvested, the tissue from hippocampus, cortex, 
midbrain and cerebellum was separated from each other and lysed in PLB for 
luminometer analyzes. 
 
Fig. 25 Methysticin feeding activated Nrf2 in the hippocampus and cortex of ARE-luciferase reporter gene 
mice. Nrf2 activation due to methysticin application was investigated in ARE-luciferase reporter gene mice. Animals 
were treated with methysticin at three consecutive days by oral gavage. Brains were prepared as described in the 
method section. Hippocampus, cortex, midbrain and cerebellum were separated and homogenized. The homogenates 
were used in a luminometer assay as recommended by the manufacturer. Methysticin significantly induced Nrf2/ARE 
activity in the hippocampus (A) and cortex (B) of treated animals. There was no effect on Nrf2/ARE activation in 
midbrain (C) and cerebellum (D). Data represent mean + SEM; n = 6; * p < 0.05 vs. untreated; 2-tailed Mann-
Whitney U test (GraphPad Prism 5, La Jolla, USA). 
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Methysticin treatment of ARE-luciferase reporter gene mice resulted in a 
significant increase of Nrf2 activity in the hippocampus and the cortex but not in 
the midbrain and cerebellum. The luminometer assay revealed that Nrf2 was 
induced in the hippocampus (14 % over untreated) and in the cortex (41 % over 
untreated) after methysticin treatment (Fig. 25A and B). Methysticin 
administration did neither affect Nrf2 activity in the midbrain (Fig. 25C) nor the 
cerebellum (Fig. 25D). 
Methysticin reduces cognitive impairments in APP/Psen1 mice 
After the efficacy of methysticin to induce Nrf2 in the brain regions of interest 
(hippocampus and cortex) was verified, long-term administration of methysticin in 
APP/Psen1 mice was carried out. The animals got methysticin once a week and 
feeding started with an age of 25 weeks and was continued for 27 weeks until the 
animals were 52 weeks of age. Afterwards the mice were tested in several 
behavioral tests to characterize possible phenotypic changes due to the 
methysticin treatment. An open-field test was conducted to get information about 
the general constitution and species-specific behavior of investigated mice. The 
general setup of the Open-Field is illustrated in Fig. 26A. The administration of 
methysticin neither affected the physical condition nor species-specific behavior of 
the animals, since neither the methysticin-treated nor the untreated APP/Psen1 
mice differed from age-matched wild-type control animals in the open field test. All 
three groups spent approximately 50 % of the total time in corners, 40 % at the 
sides, and only 10 % in the center of the maze (Fig. 26B), which is within the 
expected normal range. The mice did not differ with regard to their physical 
condition; all animals covered approximately 20-30 m during the experiment, at a 
mean speed of approximately 0.05 m/sec. Animals treated with methysticin 
exhibited slightly reduced movement, but the reduction was not statistically 
significant (Fig. 26C & D). 
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Fig. 26 Animals’ physical condition is affected neither by APP/Psen1 transgene nor methysticin treatment. To 
investigate the animals’ physical condition and species-specific behavior, a square open field apparatus with an edge 
length of 50 cm was used. The maze was divided into 3 areas: corners, sides, and the center (A). All animals were 
tested once. They were allowed to explore the maze freely for 10 min. The relative amount of time spent in each zone 
was determined for each treatment group (B). Furthermore the covered distance (C) and mean speed (D) were 
recorded. There were no differences regarding the physical condition between the investigated groups. Data represent 
mean + SEM; n = 6. 
To test the animals’ ability to access and process short-term memory information a 
Y-maze was used. The general setup of the maze is illustrated in Fig. 27A. Working 
memory was also not affected in untreated APP/Psen1 mice or in the methysticin 
treated animals, as compared to the control mice in the Y-maze evaluation.
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All three groups exhibited a spontaneous alteration (%SA) of 50-60 %, with no 
significant differences among the groups (Fig. 27B). All animals covered a 
reasonably equal distance of 15-20 m (Fig. 27C) at a mean speed of approximately 
0.05 m/sec (Fig. 27D). 
 
Fig. 27 Working memory is neither affected by the APP/Psen1 transgene nor by methysticin treatment. The 
mice’s working memory was tested in a Y-maze. The maze was composed of three identical arms arrayed at 120° 
angles to each other. The arms’ dimensions were W x H x D: 9 cm x 16 cm x 40 cm (A). All animals were tested 
once and had 6 min to freely explore the maze. Each mouse was initially placed in arm C. Total visits of all arms 
were counted, and the sequence of visits to each arm was recorded. The spontaneous alterations were determined as 
depicted in equation 3 (B). Furthermore the covered distances (C) and mean speed (D) were recorded. There were no 
differences neither regarding the physical condition nor working memory performance between the investigated 
groups. Data represent mean + SEM; n = 6. 
Due to the fact that long-term memory is affected in patients suffering from AD, the 
effect of methysticin on long-term memory abilities was particularly important in 
this study. A radial Morris-water maze was used to test the animals’ ability to 
process information over a longer period. The general setup of the maze is 
illustrated in Fig. 28A. 
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Fig. 28 Methysticin treatment ameliorates amyloid-beta-mediated long-term memory decline in APP/Psen1 
mice. To analyze long-term memory a Morris water maze test was performed. The apparatus measured 120 cm in 
diameter. All animals were passed through a 5-day protocol consisting of 2 sessions with 3 trials each day. For the 
training sessions, the animals were either inserted at different starting points with a constant platform position, or the 
platform position was alternated with the animals starting from a constant position. In the test trials, all animals 
started between O and ∆, and the platform was placed at position 1 (A). Track plots were recorded for every trial; a 
representative plot of the test trials is shown (B). To gather information about long-term memory, latency (time 
needed to find the hidden platform) was recorded during the test trials (C). APP/Psen1 mice showed a significant 
decline in long-term memory performance compared to age-matched wild-type littermates. Methysticin treatment 
rescued this effect significantly. Data represent mean + SEM; n = 6; * p < 0.05, as indicated in the chart; One-way 
ANOVA with Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, USA). 
The Morris water maze revealed that APP/Psen1 mice were severely impaired in 
terms of long-term memory. The latency (the time it took them to find the hidden 
platform) of untreated APP/Psen1 mice was significantly increased compared to 
their age-matched wild-type littermates (Fig. 28C, gray bar: 28.3 sec vs. 18.0 sec). 
Methysticin treatment rescued this long-term memory decline. The methysticin-
treated APP/Psen1 mice found the platform within 19.7 sec (Fig. 4C, gray 
patterned bar). These data were further confirmed by the track plots (Fig. 28B). 
Learning curves were plotted to exclude that observed differences were just based 
on different learning capability of the tested groups instead of their ability to 
access and process long-term memory information. 
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Fig. 29 Learning process was not different between the groups. Investigation of learning capability was conducted 
with the help of learning curves. Therefore, the latency of all training trials was plotted against the appropriate trial 
(A). For statistical evaluation the AUC was calculated for each group. (B). All animals exhibit equal learning 
capability because no differences were found between the investigated groups. Data represent mean + SEM; n = 6; 
AUC calculation and proximate One-way ANOVA with Bonferroni’s multiple comparison post hoc test (GraphPad 
Prism 5, La Jolla, USA). 
The learning ability of all groups was comparable. An AUC (area under the curve) 
analysis (Fig. 29A) revealed no statistical difference among the learning curves 
(Fig. 29B) of the investigated treatment groups. 
Methysticin does not affect Aβ plaque load in APP/Psen1 mice 
After all behavioral tests were completed, the animals were sacrificed and the 
tissue was prepared for histological and immunohistochemical examinations. The 
Aβ deposition was visualized by Congo Red staining of the brain slices and the 
amount was quantified as described in Material and Methods. 
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Fig. 30 Methysticin treatment did not significantly prevent Aβ deposition in APP/Psen1 hippocampus. To 
visualize and quantify Aβ plaque deposition, Congo red staining was conducted. Analysis focused on the 
hippocampus, highlighted by a rectangle in the representative picture of a sagittal brain section (A). Amyloid-beta 
plaque density in this area was quantified by scanning the hippocampus at 20x magnification. Single pictures were 
merged using the BZ-II Analyzer Software (Keyence, Osaka; Japan). Representative pictures of an untreated 
APP/Psen1 mouse hippocampus (B) and a methysticin-treated mouse hippocampus (C) are shown. Aβ plaques were 
counted and normalized to area of hippocampal tissue (D), and their dimensions were determined and grouped (E) 
with BZ-II Analyzer Software (Keyence, Osaka; Japan). Methysticin had no significant effect on Aβ-deposition. 
Neither overall density nor the distribution of particular plaque sizes were altered due to methysticin treatment. Data 
represent mean + SEM; n = 6; 2-tailed Mann-Whitney U test (Figure 6D), Two-way ANOVA (Figure 6E) (GraphPad 
Prism 5, La Jolla, USA). 
Scans of the whole sagittal section of the animals’ brains revealed Aβ deposition in 
all areas (Fig. 30A). For the quantification of Aβ plaque load more detailed 
microscopic pictures from the hippocampi were adduced. These were also 
obtained from scans on 40x magnification. Representative pictures of untreated 
and methysticin treated animals are depicted in Fig. 30B and C. Neither the plaque 
density (Fig. 30D) nor the distribution of plaques of particular sizes (Fig. 30E) 
differed in animals treated with methysticin. Methysticin seemed to reduce total 
amount of plaque slightly, but not to a statistically significant degree (Fig. 30D). 
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Methysticin decreases astrogliosis and microglia activation in APP/Psen1 
mice 
Neuroinflammation and astrogliosis were investigated by immunohistochemical 
detection of the common astrocyte marker glial fibrillary acidic protein (GFAP) and 
the microglia marker ionized calcium binding adapter molecule 1(Iba1). 
 
Fig. 31 Astrogliosis in hippocampi of APP/Psen1 mice is reduced by methysticin treatment. Astrogliosis was 
analyzed by immunohistochemical staining for GFAP. Pictures were generated by scanning the hippocampus at 20x 
magnification and subsequent merging of these pictures to a single picture. The upper lane shows representative 
pictures of wild type (left), untreated APP/Psen1 (middle) and methysticin-treated APP/Psen1 (right) mouse 
hippocampi. The lower lane provides pictures at 40x magnification of the same groups. Scale bars: upper 
lane = 300 µm, lower lane = 50 µm. Untreated APP/Psen1 mice show prominent astrogliosis that was significantly 
elevated compared to wild type (WT) mice. Methysticin application lead to a significant decrease of astrogliosis in 
these animals. Data represent mean + SEM; n ≥ 6; *** p < 0.001, as indicated in the chart; One-way ANOVA with 
Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, USA). 
52 weeks old APP/Psen1 mice showed a stronger astrogliosis in the hippocampus 
than age-matched wild-type animals (Fig. 31, 1st and 2nd columns). Methysticin 
feeding was able to reduce the amount of reactive astrocytes in this region (Fig. 31, 
3rd column). Semi quantitative statistics of this staining confirmed these findings. It 
revealed a significant increase of staining intensity in untreated APP/Psen1 mice 
(4.17 fold of control animals). Methysticin treatment lead to a prominent reduction 
of GFAP-positive stained cells as demonstrated by a significant reduction of 
staining intensity (Fig. 31, 3rd column; reduction to 1.77 fold of control). 
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Fig. 32 Microglia activation in hippocampi of APP/Psen1 mice is reduced by methysticin treatment. 
Microgliosis was analyzed by immunohistochemical staining with an antibody against Iba1. Pictures were generated 
by scanning the hippocampus at 20x magnification and subsequent merging of single pictures. The upper lane shows 
representative pictures of wild type (left), untreated APP/Psen1 (middle) and methysticin-treated APP/Psen1 (right) 
mouse hippocampi. The lower lane illustrates more detailed pictures at 40x magnification of the same groups. Scale 
bars: upper lane = 300 µm, lower lane = 50 µm. Untreated APP/Psen1 mice showed a significant increase of activated 
microglia compared to wild type (WT) mice. Methysticin treatment significantly decreased microgliosis in 
APP/Psen1 animals. Data represent mean + SEM; n ≥ 6; *** p < 0.001, as indicated in the chart; One-way ANOVA 
with Bonferroni’s multiple comparison post hoc test (GraphPad Prism 5, La Jolla, USA). 
Similar and even more obvious effects were found for microglia infiltration. 
Untreated aged APP/Psen1 mice exhibit massively increased labeling of microglial 
cells in the hippocampus as compared to age-matched wild-type animals (Fig. 32, 
1st and 2nd columns). This extensive infiltration of immune cells was almost 
suppressed by methysticin administration. Semi quantitative statistics of Iba1 
staining revealed a significant increase in untreated APP/Psen1 mice (3.78 fold 
Iba1 of control). Methysticin treatments led to a substantive reduction of 
Iba1-positive stained cells as well (Fig. 32, 3rd column; reduction to 1.45 fold of 
control). 
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DISCUSSION 
Nrf2 was mainly described as the key regulator in oxidative stress response in 
Mammalia 62-66. Based on its ability to induce the expression of important enzymes 
involved in the defense against upcoming reactive oxygen species, Nrf2 especially 
plays a major role in the pathogenesis of various diseases, which are known to be 
accompanied by elevated ROS levels. Most diseases are characterized by extensive 
inflammation and tissue destruction leading to the formation of reactive oxygen 
species, which subsequently cause sustained stress and tissue injury 67-70. 
Therefore, Nrf2 seems to be highly necessary to prevent the tissue from 
destruction. In 2011, our workgroup showed that in a mouse model of Rheumatoid 
Arthritis (antibody induced arthritis; AIA) Nrf2 deficiency led to increased 
oxidative stress, more extensive cartilage destruction and more pronounced 
pathogenesis. Furthermore, in a longitudinal approach with ARE-luciferase mice 
we showed, that Nrf2 was time-dependently activated during AIA treatment 25. 
These results already indicated the impact of Nrf2 activity during inflammatory 
processes. 
The aim of this thesis was to further investigate the role of Nrf2 and to clarify its 
prevailing involvement in inflammatory and degenerative processes in vitro and 
in vivo. The underlying mechanisms should be examined in detail to get a better 
insight into the precise role of Nrf2 during inflammation. 
Pro-inflammatory mediators induce Nrf2 
Much research has been done in the past and is still ongoing regarding the 
mechanisms involved in the resolution of inflammation. It is known that a 
sufficient resolution of inflammation is indispensable for the complete 
regeneration of the injured tissue. Therefore a lot of approaches are especially 
focused on macrophage polarization. Macrophages can be phenotypically 
distinguished by the expression of either pro-inflammatory or anti-inflammatory 
markers 71. The resulting subpopulations are called M1 (pro-inflammatory) and 
M2 (anti-inflammatory) macrophages. It is known that initially M1 macrophages 
are responsible for the clearance of pathogens, all types of pathogenic objects and 
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injured tissue. These macrophages are mainly driven by the pro-inflammatory 
transcription factor NF-κB and boost thereby the inflammation by the secretion of 
pro-inflammatory cytokines and chemokines 72. Furthermore it is described that 
after the clearance, M2 macrophages in the tissue are critically involved and 
necessary for tissue regeneration. It has been shown, that Nrf2 activity during 
inflammation is not necessarily mediated by upcoming oxidative stress, but can 
also be induced by inflammatory mediators 19. Stimulation of THP-1, RAW264.7 
and primary murine BMDM showed that TNF-α is able to induce Nrf2 in a time-
dependent manner (Fig. 9). Especially the observed time-dependency was very 
interesting, because a significant induction was not observed before 6–12h 
treatment. Considering that the Nrf2/Keap1 system is conceived to react 
immediately in response to stimuli 73 usually within 3h, the observed delayed 
activation was surprising. The following stimulations with various 
pro-inflammatory cytokines (Fig. 10) and PAMPs (Fig. 11) further confirmed these 
findings, indicating that a kind of signaling cascade has to be interposed. 
Interestingly, anti-inflammatory stimuli like IL-4 and IL-10 (Fig. 12) were not able 
to induce Nrf2 activity, restricting Nrf2’s involvement during inflammation to the 
initial pro-inflammatory phase. It is known that the complex receptors, which are 
activated by these cytokines, are able to induce downstream MAP kinase signaling 
as well as NADPH oxidase 2 (NOX2) activation 74,75. The involvement of many 
intermediate steps would explain the observed delayed Nrf2 activation. Therefore 
further experiments were conducted with TNF-α to clarify this issue exemplarily. 
Actually it was shown that reactive oxygen species (ROS) and especially 
superoxide are produced due to TNF-α treatment of macrophages 76,77, indicating a 
possible involvement of the NOX. This implication was strengthened by the use of 
specific NOX inhibitors (Fig. 13). As ROS induce Nrf2 itself but are also described to 
induce MAP kinase activity 78, experiments with specific kinase and NOX inhibitors 
followed. Clearly, it was found that NOX, ERK1/2 and p38 kinase are critically 
involved in the investigated signaling cascade (Fig. 14). The question raised what 
physiological meaning remains behind this signaling. Out of the many well-known 
Nrf2 target genes, heme oxygenase-1 (HO-1) is more or less the most adjustable 
and interesting enzyme in this context. On the one hand HO-1 breaks down heme 
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to biliverdin, which is described to be an antioxidant and therefore highly 
necessary during oxidative stress defense. On the other hand carbon monoxide is 
simultaneously produced by this HO-1 driven degradation of heme 79,80. Moreover 
the produced carbon monoxide is able to efficiently inhibit the pro-inflammatory 
transcription factor NF-κB 57,58, which makes HO-1 activity not only antioxidant 
but also anti-inflammatory. For that reason HO-1 expression beside other Nrf2 
targets was investigated more intensively. The qRT-PCR and western blot 
experiments revealed that HO-1 is significantly induced in macrophages after 
TNF-α treatment (Fig. 15), demonstrating an important link between Nrf2 
activation and the termination of pro-inflammatory conditions. Based on these 
in vitro data it can be supposed that pro-inflammatory stimuli act double tracked 
on immune cells. Directly after receptor binding these mediators cause a fast 
acting NF-κB mediated inflammatory response as already well-described.  
 
Fig. 33 Model of cytokine/PAMP induced signaling in macrophages. Predicted signaling cascade initiated by 
pro-inflammatory mediators. Fast-acting NF-κB signaling initiates inflammation and expression of pro-inflammatory 
cytokines (orange cascade). Slow and delayed acting Nrf2 signaling counteracts NF-κB signaling due to Nrf2-
dependent CO production (blue cascade). 
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Additionally this interaction starts a prolonged activation of Nrf2 in parallel, which 
is delayed because of a couple of intermediate steps including the production of 
superoxide at first and the anti-inflammatory carbon monoxide at the end (Fig. 33). 
That means these pro-inflammatory mediators simultaneously induce 
inflammation as well as the temporally shifted resolution of inflammation. 
Verification of this consumption was found in the subsequently conducted LPS 
tolerance experiments. These experiments clearly demonstrated that Nrf2 
presence significantly influences LPS mediated NF-κB activity (Fig. 16A-C) as well 
as the ability of macrophages to undergo LPS tolerance (Fig. 16D & E). Nrf2 
deficiency resulted in significantly increased NF-κB activity, causing a more 
extensive inflammation. Likewise Nrf2-KO macrophages were not able to develop 
LPS tolerance, resulting in continuous production of the pro-inflammatory 
cytokines TNF-α and IL-6. Certainly, knocking out Nrf2’s inhibitor Keap1 resulted 
in exactly the opposite effect. NF-κB activation and cytokine production was 
significantly reduced due to LPS single treatment. Moreover these cells showed an 
enhanced LPS tolerance after double treatment. This in vitro study clearly exhibits 
the impact of Nrf2 during the progression and resolution of inflammation. Nrf2 is 
not only responsible for the anti-oxidant defense during this process but has also 
important functions in the regulation of macrophage polarization and thus the 
resolution of inflammation. 
Nrf2 determines the fate of inflamed synoviocytes 
Recently, our group showed that oxidative stress is significantly involved in 
cartilage degradation in experimental arthritis and that Nrf2 activity is a major 
requirement for limiting cartilage destruction 25. Other detrimental factors are 
unbounded inflammation and rampantly growing pannus, invading the cartilage 
and the bone. The data suggest that the pro-inflammatory transcription factors 
NF-κB and AP-1 mediate pannus formation via induction of synoviocyte 
proliferation and resistance against apoptosis 81. 
Since it was previously observed that Nrf2 plays a critical role in resolution of 
inflammation, further research was conducted in an in vitro model of Rheumatoid 
Arthritis (RA). For that purpose the synoviocyte cell lines HSE and K4IM were 
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stimulated with TNF-α to mimic inflammatory and arthritic conditions in cell 
culture. TNF-α was chosen, because the secretion of this cytokine besides IL-1β 
represents one of the hallmarks of RA pathogenesis 82-86. They boost the 
inflammatory process within the joints and thereby cause extensive destruction of 
involved structures. Furthermore the inflamed synovial membrane begins to 
proliferate due to NF-κB and AP-1 activity leading to an excessive pannus 
formation 87. 
The objective of this in vitro approach was to examine the effect of sulforaphane 
(SFN) on TNF-α pre-treated synoviocytes. First data showed that SFN has anti-
arthritic and immune regulatory effects in an in vitro and in vivo model of RA 88. In 
addition, it has been shown that SFN induces apoptosis in cancer cells, and inhibits 
the cell cycle, angiogenesis and inflammation 89,90. Contrary to that, SFN is also 
known to efficiently activate Nrf2 and thereby protect cells against oxidative 
damage 91. Based on these data, it was believed, that SFN-mediated Nrf2 activation 
might restrict the inflammatory process and enhanced proliferation of TNF-α 
pre-treated synoviocytes. Beside the Nrf2 activation, SFN by itself is able to inhibit 
the transcription factors NF-κB and AP-1, which are mainly involved in synovitis 92-
95. 
First experiments with luciferase reporter gene constructs for NF-κB and AP-1 
activity, clearly demonstrated that SFN exhibits an enormous potential to inhibit 
the activity of these transcription factors after TNF-α mediated induction. SFN was 
able to significantly reduce NF-κB as well as AP-1 activity even at the lowest 
applied concentration (Fig. 17). Moreover the secretion of TNF-α and IL-1β, both 
regulated by NF-κB, was significantly reduced by SFN as well (Fig. 18). These 
results showed that SFN is able to restrict the inflammatory process by NF-κB 
inhibition.  
There are several lines of evidence suggesting that cell cycle progression and 
transcription factor activation of synovial cells are altered towards a transformed 
‘tumor-like’ manner in RA 81. It has been demonstrated that activation of NF-κB 
and AP-1 protects cells in the synovium against apoptosis and provides a link 
between inflammation and hyperplasia. This gave first evidence that inhibition of 
NF-κB and AP-1 reduces cell viability and proliferation of inflamed synovial 
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fibroblasts 81,96-99. Based on this, it was hypothesized that NF-κB and AP-1 
activation is vital for cytokine-activated synoviocytes and, as a consequence, 
deactivation or inhibition of these factors via SFN results in cell death. Since the 
reporter gene assays revealed an inhibitory potential of SFN on NFκB and AP-1, 
further analysis regarding cell viability, proliferation and apoptosis were 
conducted. These assays showed that both the stimulation with TNF-α as well as 
SFN alone enhanced cell viability, but co-stimulation with both factors significantly 
reduced viability. Furthermore both cytotoxicity and apoptosis were not 
influenced due to the single-administration of TNF-α or SFN. Indeed, the 
co-stimulation with both factors resulted in significantly enhanced cytotoxicity and 
apoptosis. These data showed that SFN acts contrary on TNF-α pre-stimulated 
“inflamed” and healthy naïve synoviocytes. It simultaneously enhances cell 
viability of healthy synoviocytes due to Nrf2 activity on the one hand and drives 
“inflamed” synoviocytes into cell death by the induction of apoptosis on the other 
hand. Furthermore, experiments showed that not only the SFN mediated NF-κB 
inhibition but also a SFN independent Nrf2 activation led to the same effect of 
decreasing cell viability as in co-stimulated wild-type cells in the previous 
experiments. The RTCA experiments clearly revealed a Nrf2 driven decrease of 
proliferation in response to TNF-α in HSE cells stably transduced with shRNA 
directed against Keap1 (the inhibitor of Nrf2). As already shown in macrophages 
before, Nrf2 activation leads to an up-regulation of heme oxygenase-1 (HO-1) 100. 
HO-1 produces carbon monoxide, which is described to efficiently inhibit NF-κB 
activity 57,58. Hence, it is likely that the increased Nrf2 activity via Keap1 silencing 
and the resultant HO-1 mediated CO production causes a similar inhibition of 
NF-κB as SFN does, leading to the same impaired cell viability and proliferation. 
The RTCA experiment emphasizes that the observed effects of SFN on TNF-α pre-
treated cells may not only be explained by direct inhibition of NF-κB but also by 
SFN-driven induction of Nrf2 activity, which indirectly inhibits NF-κB via HO-1 
mediated CO production. 
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Nrf2 deficiency deteriorates pathological hallmarks of sclerosing 
cholangitis 
Since the previously described projects already pointed out a crucial role of Nrf2 
during inflammatory processes, the investigations regarding the pathogenesis of 
sclerosing cholangitis further supported these findings. Primary sclerosing 
cholangitis is a common and severe liver disease. It is accompanied by oxidative 
stress, inflammation, ductular reaction, bilirubinostasis, hepatomegaly and mostly 
ends up with liver cirrhosis. It is believed that especially the ongoing pro-
inflammatory environment triggers the pathogenesis of this disease 101-103. Aim of 
this study was to investigate the influence of Nrf2 on the modulation of 
pathogenesis focused on the inflammatory processes in a mouse model of 
sclerosing cholangitis induced by 3,5-diethoxycarbonyl-1,4-dihydrocolidine (DDC) 
diet 104. DDC feeding for 4 weeks resulted in typical symptoms like hepatomegaly, 
bilirubinostasis, ductular reactions in terms of proliferating cholangiocytes and 
infiltration of immune cells. This symptomatic was even more pronounced in 
Nrf2-KO mice, since these animals showed a significantly enhanced reaction 
relating to bilirubinostasis, cholangiocyte proliferation and immune cell infiltration 
(Fig. 21A). Additionally, necrotic areas were found only in the livers of Nrf2-KO 
animals (Fig. 21, inserted box). The quantification of liver weights revealed that 
the livers of both genotypes significantly increased in the course of DDC feeding. 
However, the liver weight of Nrf2-KO animals was significantly lower after DDC 
feeding compared to treated wild type animals. It is known, that after an initial 
extension of livers, ongoing DDC treatment leads to tissue destruction due to 
apoptosis and necrosis 104. Therefore, the reduced liver weights of Nrf2-KO mice 
can be explained by necrosis already occurring in Nrf2-KO but not in wild type 
animals. It is suggested that Nrf2 deficiency and the resulting vulnerability against 
oxidative stress might be the cause for the induction of necrosis 105. 
Analysis of important Nrf2 target genes, which are involved in the oxidative stress 
defense, revealed that Nrf2-KO animals were not able to counteract DDC-mediated 
stress. The transcription of heme oxygense-1 (HO-1), NADPH oxidoreductase 1 
(NQO1) and gamma glutamate-cysteine ligase (γGCS) was significantly induced 
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after DDC treatment in wild type but not in Nrf2-KO animals (Fig. 22A-C). 
Furthermore, the transcription of the pro-inflammatory cytokines TNF-α (Fig. 
22D) and IL-1β (Fig. 22E) as well as markers for cholangiocytes (Fig. 22F: Ck-19) 
and fibrosis (Fig. 22G: Coll1a) were significantly increased in treated Nrf2-KO mice 
compared to their wild type littermates. HO-1 western blot analysis revealed that 
HO-1 expression was also decreased in Nrf2-KO livers on protein level (Fig. 23), 
demonstrating a reduced antioxidant and anti-inflammatory capacity and 
increased vulnerability against upcoming stress of these animals. 
Further analysis regarding inflammation took place with the help of a multiplex 
Luminex approach to determine the release of inflammatory mediators. This 
experiment demonstrated that inflammation in general was just slightly induced in 
response to short-term DDC treatment. Both, wild type and Nrf2-KO mice, 
responded to DDC treatment with the secretion of cytokines, chemokines and 
other inflammatory mediators. Although the response was quite moderate, the 
concentration of the pro-inflammatory cytokine interferon-γ (Fig. 24B: IFN-γ) was 
significantly increased in Nrf2-KO mice but not in wild type littermates. The 
secretion of the other two investigated pro-inflammatory cytokines, TNF-α (Fig. 
24A) and IL-1β (Fig. 24C) was not affected by DDC treatment. Analysis of 
anti-inflammatory cytokines revealed similar effects. The secretion of IL-5 (Fig. 
24D) and IL-10 (Fig. 24F) was only induced in treated Nrf2-KO animals, 
demonstrating an ongoing inflammation in these animals but not in wild types. 
Chemokines represent a specialized class of proteins, which are secreted during 
inflammation to attract immune cells. In this context, CCL2 was found to be 
induced in wild type as well as Nrf2-KO animals after DDC diet (Fig. 24H). In 
contrast, CCL4 was only induced in Nrf2-KO mice (Fig. 24I). There was no effect of 
DDC treatment on the secretion of CXCL1 (Fig. 24G). Basically, it can be concluded 
that short term DDC treatment induced inflammation only to a moderate extent. 
Nevertheless, Nrf2-KO mice showed a significantly enhanced inflammatory 
response to this treatment. 
Taking these findings into account, this project revealed a protective role of Nrf2 
during the pathogenesis of sclerosing cholangitis. The results indicate that this 
protection is based on Nrf2’s ability to counteract oxidative stress on the one hand, 
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but also modulate the inflammatory process itself on the other hand. Since HO-1 
was already highlighted in the former projects to act anti-inflammatory, it can be 
suggested that the impaired HO-1 induction in Nrf2-KO livers after DDC feeding 
might have significant impact on increased inflammation and tissue destruction in 
these animals. This hypothesis is further strengthened by the current literature. 
Onyiah et al. already reviewed the role of HO-1 in the regulation of intestinal 
inflammation. They demonstrated that HO-1 and the resulting CO production 
ameliorates intestinal inflammation 16. Zhou et al. were able to up-regulate HO-1 
via Nrf2 activation by sulforaphane treatment in vivo as well as in vitro and 
demonstrated a cytoprotective function of HO-1 in an ethanol-induced fatty liver 
model 23. HO-1 revealed cytoprotective properties by the inhibition of 
inflammation in a model of non-alcoholic fatty liver disease as well 20. These 
studies and the data from this thesis suggest Nrf2 as a potential target for 
therapeutic intervention during liver diseases to counteract up-coming oxidative 
stress as well as inflammation. 
Nrf2 induction counteracts neuro-inflammation during AD 
pathology 
Alzheimer’s disease (AD) is one of the most common neurodegenerative diseases 
of elderly people. During the past decades AD got more and more impact, as 
improved medical maintenance resulted in prolonged life span and delayed 
mortality in our society. AD typically comes along with divergent hallmarks, like 
the accumulation of miss-folded amyloid-beta (Aβ) peptides, forming Aβ-plaques, 
hyperphosphorylation of tau peptide, astrogliosis and neuroinflammation in the 
form of microglia infiltration. These pathological changes finally lead to severe 
neurodegeneration and cognitive impairments like the disturbance or loss of 
long-term memory performance right up to bedriddenness in the end 106. Up to the 
present day, the initial cause of AD is still unknown and therefore current research 
is mainly focused on therapeutic approaches that target AD-associated 
symptomatic. Moreover, there exists no cure for AD, mainly because of the inability 
to detect the disease before it has progressed so far, that memory loss and 
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functional decline already appeared. Former in vitro experiments of our group, 
using the neuronal PC12 cell line revealed that the pharmacological induction of 
Nrf2 by several kavalactones resulted in increased cell viability and enhanced 
resistance against Aβ-mediated cytotoxicity 61. Further evidence that Nrf2 
activation is neuroprotective against Aβ-toxicity was provided by Kanninen et al., 
whose elegant genetic approach demonstrated that viral transduction of Nrf2 into 
the hippocampus of APP/Psen1 mice improves their spatial memory 107,108. These 
studies proved the conceptual validity of Nrf2-activation approaches to 
Alzheimer’s disease, but did not provide a practically feasible therapeutic approach 
for a widespread disease like AD. Based on our findings, one of the used 
kavalactones was chosen to be studied in an in vivo model of Alzheimer’s disease. 
For this study, animals from the transgenic C57BL/6.Cg-Tg(APP695)3Dbo 
Tg(PSEN1dE9)S9Dbo/J strain (APP/Psen1) were fed with methysticin once a week 
by oral gavage. Methysticin is a plant content and belongs to the class of 
kavalactones. It originates from kava kava (lat.: Piper methysticum) and exhibits 
electrophilic properties, which empowers this molecule to efficiently induce Nrf2. 
The effects of methysticin treatment were analyzed phenotypically with a couple of 
behavioral tests, before brain tissue was gained for following analysis. Initial 
open-field testing showed that methysticin had no effect on general constitution or 
behavior of investigated animals (Fig. 26). That means that the treatment did 
neither affect species-specific behavior like fear/anxiety or exploratory curiosity 
nor their locomotion. Following Y-maze analysis confirmed data from literature 
that even the untreated APP/Psen1 animals’ short-term memory was not affected 
in this mouse model 28. Additionally, methysticin did not affect short-term memory 
(Fig. 27). All investigated animals exhibited equal performance compared to their 
age-matched wild type littermates. These finding are in line with AD pathology in 
humans, as initially the short-term memory is not influenced by the disease. 
However, mainly the processing of newly acquired information into long-term 
memory is usually impaired in those patients 29. Because of that, long-term 
memory performance was tested using a Morris-water maze approach. This 
experiment clearly demonstrated that long-term memory was severely impaired in 
untreated 52 weeks old APP/Psen1 compared to age-matched wild type 
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littermates. Interestingly, treatment of these transgenic animals with methysticin 
over 6 months completely rescued this cognitive decline (Fig. 28). The outcomes of 
our behavioral analyzes of APP/Psen1 mice treated with methysticin were 
comparable to findings from a study of Nrf2 overexpression by viral transduction 
107. Since Aβ plaque formation and resulting oxidative stress with subsequent 
tissue destruction illustrate the main pathological hallmarks of AD-associated 
neurodegeneration and cognitive impairment, Congo Red stainings should reveal 
the amount of Aβ plaque load in the brains of investigated animals. Region of 
interest in the following histological examinations was the hippocampus, because 
this structure is mainly responsible for the processing and redirection of new 
information to the long-term memory 26. With the help of this staining it was 
clearly shown that the observed improvement of cognition due to methysticin 
treatment could not be explained by reduced Aβ plaque formation, as there were 
no distinct differences ascertainable regarding total amount of Aβ plaques as well 
as the distribution of defined plaque sizes (Fig. 30). As a consequence the reason 
for a better cognitive outcome of treated animals had to be found elsewhere. 
It is described that besides oxidative stress Aβ deposition leads to 
neuroinflammation, which is characterized by an increased occurrence of activated 
astrocytes (astrogliosis) and microglia infiltration (microgliosis) into affected 
brain regions 34-36. This process is normally used to clear the affected area from 
foreign objects and to recover homeostasis. In the case of accumulated miss-folded 
Aβ the immune system is not able to remove the plaque, whereby the 
inflammatory process is continuously triggered instead of being resolved. It is 
believed that this escalating inflammation might have severe impact on the 
pathogenesis of AD 36. Immunohistochemical detection of astrocytes and microglia 
showed that untreated APP/Psen1 animals exhibit severe astrogliosis (Fig. 31) and 
microglia infiltration (Fig. 32) in the hippocampus. The enhanced inflammatory 
reaction due to Aβ was significantly reduced after methysticin treatment, like the 
effect observed in mice treated with Nrf2-expressing viruses 107. From the 
analogous character of these two studies’ outcomes and from our earlier findings 
61, it stands to reason that the beneficial effect of methysticin on APP/Psen1 mice is 
the result of methysticin driven Nrf2 activation. It has been shown that methysticin 
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induced Nrf2 activity in hippocampal and cortical region of ARE-luciferase 
reporter gene mice. As both regions and especially the hippocampus play a crucial 
role for spatial learning and memory, this effect is in line with the hypothesis of 
Nrf2-dependent improvement of long-term memory performance. These findings 
further consolidate the suggestion that Nrf2 deploys its cytoprotective function not 
only due to its antioxidant capacity but also to an immense extent due to its ability 
to direct inflammation to its resolution. Taken together, these experiments confirm 
that methysticin has anti-inflammatory properties as reported by Pollastri et al. 
2009 who used an in vitro model of LPS-mediated inflammation in which 
kavalactones inhibited LPS-induced TNF-α secretion 37. As already mentioned, 
neuroinflammation plays an important role in the pathophysiology of AD. It may 
contribute to an Aβ-independent neural dysfunction and cell death, such that a 
self-perpetuating cycle becomes established by which inflammation feeds further 
neurodegeneration. Therefore, anti-inflammatory treatment via Nrf2 activation 
may represent an appropriate therapy for AD. In prospective studies, anti-
inflammatory treatments have delayed AD onset and alleviated or slowed 
cognitive decline 38. In contrast to these approaches, the pharmacological induction 
of Nrf2 would not only counteract inflammation but would also support the 
healthy tissue via up-regulation of cytoprotective enzymes. These findings indicate 
that treatment of AD patients with methysticin might be considered as a novel 
therapeutic strategy to combat neuroinflammation and neurodegeneration. 
Furthermore, methysticin might be taken into account as an interesting nutritional 
supplement for a preventive strategy against AD. 
CONCLUSION 
106 
CONCLUSION 
In conclusion, all presented projects conducted in the course of this thesis share 
one important fact. It was shown, that in all investigated models the regulation of 
the inflammatory process plays a critical role for an efficient recovery from 
disease. The study demonstrated that uncontrolled inflammation leads to 
continual tissue destruction in liver and brain due to the escalating stress within 
the affected tissue. Much research focuses on the modulation of the inflammatory 
process to find therapeutical approaches to combat miss-leaded inflammation 
during the pathogenesis of diseases and to promote tissue regeneration. This work 
firstly presents Nrf2 as a key regulator involved in the resolution of inflammation. 
It was shown that early pro-inflammatory mediators actuate a double tracked 
molecular machinery. Besides the well-known NF-κB signaling, which initiates the 
acute phase of inflammation, these mediators induce Nrf2 delayed in time. The 
obtained data emphasized the impact of the delayed Nrf2 activity during 
inflammation, since the experiments clearly demonstrated that this activation led 
to increased HO-1 expression. HO-1 subsequently produces carbon monoxide, 
which efficiently inhibits NF-κB and interrupts pro-inflammatory signaling. 
Consequently it has been shown that Nrf2 thereby occupies an important place in 
the formation of LPS tolerance in macrophages. Pena et al. was able to show that 
the formation of this tolerance can be looked upon as a switch from the 
pro-inflammatory M1 macrophage to the anti-inflammatory M2 phenotype 39. The 
insights from this in vitro study provided the basis for further investigation in the 
other projects. Nrf2 activity embarrassed the proliferation of inflamed 
synoviocytes due to NF-κB and AP-1 inhibition, whereby pannus formation in the 
course of Rheumatoid Arthritis might be prevented. Simultaneously it 
strengthened healthy synoviocytes to counteract upcoming stress. Nrf2 deficiency 
led to more severe tissue destruction and inflammation in the liver due to reduced 
HO-1 expression after DDC feeding. Finally it was possible to show that the 
pharmacological induction of Nrf2 results in reduced neuroinflammation in a 
murine Alzheimer’s disease model, whereby the cognitive decline accompanied 
with AD pathology was completely rescued. 
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Overall, it can be suggested that Nrf2, in addition to its classical function as the key 
regulator of the oxidative stress defense system, assumes an important role during 
inflammation by directly leading this process to its resolution. Nrf2 can be 
assumed to act anti-inflammatory, which makes Nrf2 a potential target for 
therapeutical approaches combating inflammation-associated diseases. 
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Insert sequences 
Both inserts were designed to exhibit a PstI and a NheI restriction site at the ends 
after annealing. Both restriction enzymes produce sticky ends, therefore the sense 
and antisense oligos have different lengths. Core sequences of the response 
elements are highlighted in red, sticky ends in green (PstI) and orange (NheI). 
ARE_Lenti-s (22mer): 
5'-GTCACAGTGACACAGCAGAATG-3' 
ARE_Lenti-as (30mer): 
5'-CTAGCATTCTGCTGTGTCACTGTGACTGCA-3' 
NFkB_Lenti-s 5'-(59mer): 
5'-GATGTGGGATTTTCCCATGAGTGAGGGGACTTTCCCAGGCATGTGGGATTTTCCCATGG-3' 
NFkB_Lenti-as 5'-(67mer): 
5'-CTAGCCATGGGAAAATCCCACATGCCTGGGAAAGTCCCCTCACTCATGGGAAAATCCCACATCTGCA-3' 
Restriction sites are as follows: 
PstI (3’ overlap): 
CTGCA^G 
G^CTAGC 
NheI (5’ overlap): 
G^CTAGC 
CGATC^G 
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